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Abstract
Praziquantel (PZQ) is the drug of choice for treatment of schistosomiasis since its
discovery in 1972.1,2 According to World Health Organization (WHO), schistosomiasis is the
second most prevalent parasitic disease worldwide that has no effective vaccine yet. Schistosoma
parasites infect more than 200 million people in about 76 countries and about 700 million people
are at risk. 3,4 PZQ is not only used for treatment of schistosomiasis, but it is also used for control
of other parasitic diseases and it is included on the Model List of Essential Medicines of WHO.5,6
Parasitic diseases, despite their significant global burden, have been rather under
researched by drug discovery companies as compared to other diseases mainly due to
complexities of parasitic infections and lack of economic motivations. In such scenario,
nanomedicine has a crucial role to play in improvement of the current anti-parasitic agents by
their delivering in a targeted manner to the schistosome parasites in host blood circulation.
Hence, selective drug delivery is an important approach with great potential for overcoming
problems associated with the systemic toxicity and poor bioavailability of PZQ.
This study aims at overcoming the inherent drawbacks of PZQ through formulation,
optimization and evaluation of PZQ-loaded biodegradable PLGA “Poly (D,L lactide-coglycolide)” nanoparticles (NPs) that were surface conjugated with polyclonal antibodies (pAb)
specific for schistosome surface antigens (sAg) for active targeting and treatment of
schistosomiasis.
PZQ was encapsulated in biodegradable PLGA NPs using single emulsion-solvent
evaporation method. Various parameters were investigated and optimized like drug: polymer
ratio, surfactant concentration and osmotic effect of adding salts to the external aqueous phase.
PZQ-loaded NPs were characterized for drug content and drug release rate using HPLC, particle
i

size, particle size distribution and ζ-potential using dynamic light scattering, surface morphology
using scanning electron microscopy (SEM) and atomic force microscopy (AFM), and drug
physical and chemical integrity using differential scanning calorimetry (DSC) and Fourier
transform infrared (FTIR) spectroscopy. Spherical PLGA NPs with smooth and discrete surface
were prepared. The physicochemical properties of the prepared NPs were investigated and the
optimum formulation was selected. The selected formulation was monodispersed NPs
200.8±4.02nm in diameter and negatively charged surface (-21.03±3.08mV). PZQ- loaded
PLGA NPs showed sustained release profile from the optimum formulation with the highest
encapsulation efficiency and drug loading (94.19±3.46% and 47.09±3.46% respectively).
Specific anti- schistosomal pAb specific against schistosome sAg was prepared, purified
and characterized. Surface functionalization of the optimized PZQ-loaded PLGA NPs with antischistosomal pAb was then achieved using both physical adsorption and chemical conjugation
methods using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and Nhydroxysuccinimide (NHS) mediated cross linking agents. The pAb- conjugated immuno-NPs
showed higher coupling efficiency than the pAb- adsorbed NPs (89.31±1.78 and 64.2±2.87%,
respectively). Re-evaluation of the physical properties of NPs and the reactivity of pAb after
coupling reactions was performed. The immuno-NPs indicated optimum properties with
preserved bioactivity of the attached antibodies.
Thus, it was concluded that pAb-conjugated PLGA NPs provide an efficient and targeted
delivery of PZQ, presenting a potential preliminary delivery system for treatment of
Schistosomiasis in near future.

Key Words
Praziquantel – Schistosomiasis – PLGA – Nanoparticles – Immuno-nanoparticles –Adsorption – EDC/
NHS – Surface Functionalization –Schistosomicidal
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Introduction
Schistosomiasis (Bilharziasis) is a blood disease caused by a trematodal parasite of
genus Schistosoma (Bilharzia). Bilharzia was named after the German surgeon Theodore Bilharz
who discovered it in 1851 in Egypt and found that Schistosoma haematobium is the causative
agent of the disease. Schistosomiasis is considered to be the second most destructive disease,
after malaria, in the tropical countries.

7–9

It is an epidemic disease that affects more than 200

million people worldwide and more than 700 million are at risk in more than 76 different
countries. Mortality has been estimated to be 280,000 deaths/ year in Sub-Saharan Africa.
Schistosomiasis presents in wide spectrum disease including both acute and chronic forms,
affecting multiple target organs.

4,10,11

Figure 1 shows the worldwide epidemiological distribution of

schistosomiasis.
There are more than five different species that cause schistosomiasis. The most widely spread

species is Schistosoma mansoni which is found in Africa (some subtropical and tropical regions),
the Caribbean, the Middle East and South America. The second species is named S.
haematobium and is spread in Egypt, Sub-Saharan Africa, India North Africa and Middle East.
The third type is called S. japonicum which is only prevalent in Asia. The fourth type, S.
intercalatum, is present more in West and Central Africa, while the fifth type is called S.
mekongi and is only present in Cambodia and Laos. 3,12,13
The life cycle of all species of Schistosoma is the same. Schistosoma worms are either
males or females. The female worm is thin and tall and stays in a groove in the male body called
the gynecophoric channel. Schistosoma worms have two hosts; the primary host (human) and the
secondary host (fresh water snails). Sexual life cycle takes place in humans while asexual one
takes place in the snails. Not all snails act as a secondary host, only some as Biomphalaria for S.
mansoni, Bulinus for S.haematobium and Oncomelania for S. japonicum.3,12–15 Figure 2 is an
illustration of Schistosoma life cycle.
As a neglected tropical disease (NTD) and like many other “damaging” parasitic
diseases, no enough efforts go for finding solutions for suffering of such a huge number of
people worldwide.16 Since its detection on 1851, no treatment was efficient enough for the
1

control of such an infection until the discovery and production of praziquantel (PZQ) in 1972 by
“Bayer and Merck” pharmaceutical company.
Praziquantel is a pyrazino-isoquinolone derivative (Figure 1.15) characterized by its
broad spectrum activity against a wide range of parasites other than Schistosoma. The
“polyparasitism” capacity of PZQ has made it the drug of choice for treatment of many parasitic
infections. 17–19
PZQ greatly helped in controlling the spread of schistosomiasis in many countries.
However, it did not prevent its spread because of several interconnected factors. One reason is
the development of water resources in several tropical countries which has probably contributed
to maintain these figures at relatively constant –

if not increasing – levels in recent years. As

these water resources contribute to the spread of the not- easy to control snails that act as the
intermediate hosts.5,17,17
Since no vaccine exists against schistosomiasis, chemotherapy is the main approach for
schistosomiasis control till nowadays. PZQ is

currently the only available anti-schistosomal

drug and it is distributed mainly through mass administration programs to millions of

people

every year. By time and by depending on only one drug for treatment and control of such an
infectious disease (Massive and repeated use on large numbers of individuals), the development
of drug resistance is a much feared possibility. Resistance of schistosome parasites against PZQ
started already to appear in different places in the world.20,21
Development of resistance against PZQ is a serious challenge that alarms the scientific
community to find a solution and fasten the research done to discover new chemotherapeutic
agents or vaccine for control of schistosomiasis. The issue is that the process of discovery of
novel drug and its approval by FDA is a very long procedure that needs several years and
billions of dollars. To that time, there should be other solutions.
However, development of resistance is not the only problem associated with PZQ. There
are many other drawbacks linked with this drug. For example, the main available dosage form
(DF) of PZQ in the market is the oral tablets. PZQ suffers from first pass metabolism by the liver
when taken orally that converts about 80% of the administered dose to completely inactive
metabolites. This necessitates its administration in very high doses to compensate for the
2

metabolized and inactivated part of it; which, in turn, exposes the patient to its side effects, helps
the parasite to develop resistance against the drug, in addition to its socio-economic impact. As it
will be more costing and will not be available for all who need it especially that this disease is
epidemic in very poor countries as mentioned above. 22–24
Other problems associated with PZQ being administered in a traditional oral dosage form
is it distribution in the whole body exposing different organs to the drug while not in need for it.
Its fast elimination necessitates re-administration as patients are susceptible for exposure and reinfection with the parasite. Another major flaw of PZQ is its lack of efficacy against the
immature stages of the parasite.
All these reasons push scientists for finding a solution for such a problem. Since finding a
new drug from scratch will let people suffer for long time waiting for it, other solutions should
be found all that time. Various options may be useful.
Firstly, development of an effective vaccine would be great; unfortunately, no successive
trial was achieved. This might be due to the complexity of the host – parasite interaction as
Schistosoma worms can evade the host immune response and live in the host blood circulation
for 5 to 20 years. The host defense mechanisms start only when eggs were being laid or against
the dead worm after treatment.22–28
Another possible approach is finding new indications (schistosomicidal effect) of already
FDA approved drugs for treatment of other diseases. A large number of compounds have been
tested as potential anti-schistosomal agents. For example, many antimalarial drugs such as
mefloquine and artemether showed anti-schistosomal effects in vitro and on infected mice. Some
of them are promising, but none so far represents a suitable substitute or adjunct to PZQ.

29–33

Research should be continued to select the most effective drug that we could depend on it for
treatment of schistosomiasis either alone or as combination therapy with PZQ. The research of
new anti-schistosomal compounds is an imperative and urgent matter.17
More realistic and hopeful solution is overcoming the inherent problems and improving
the physico-chemical properties of the currently used and most effective drug, PZQ. This could
be achieved by applying and benefiting from the recent advances in bio- nano technology
solutions to design and develop targeted nano-carrier drug delivery systems that will solve many
3

of the inherent drug drawbacks. Then, further formulate them in suitable dosage forms to be
available for suffering patients and people worldwide.
Nanotechnology is involved in the design, synthesis, characterization and application of
materials and devices whose smallest functional organization is on the nanometer scale at least
on one dimension. The clinical applications of nanotechnology in the pharmaceutical field either
take advantage of the unique properties of drugs in the nano-range or the incorporation of drugs
into nano-carriers to control drug release, drug targeting, or salvage of drugs with low
bioavailability. Nanocarriers can be made from a variety of materials such as lipids (liposomes,
solid lipid nanoparticles), polymers (nanoparticles, micelles, dendrimers) and inorganic carriers
(gold nanoparticles, carbon spheres and nanotubes). According to the manufacturing methods
and materials used, these carriers may have different shapes and sizes with distinct properties.34–
38

Nanoparticles (NPs) in the field of nanotechnology have been emerging as key
mechanisms by providing a targeted approach for efficient delivery of conventional
chemotherapeutic drugs for cancer therapy. This targeted approach leads to the delivery of drugs,
in low dosages, in a sustained manner for an efficient action within the body. NPs are nano-sized
stable, colloidal or solid particles, generally made of biodegradable polymer or lipids. They
entrap or encapsulate the active principal or adsorb or attach to their surface. 38–41
In our case, to overcome the inherent drawbacks of PZQ so that it could be more
effective chemotherapy for control and treatment of schistosomiasis, PZQ could be first loaded
into polymeric nanoparticulate carriers.
Polymeric NPs are considered a versatile medium for the delivery and monitoring of
therapeutic compounds in vivo due to their enhanced biological stability and extended in vivo
circulation. They account for more than 80% of the available therapeutics in clinical use. The
increased interest in using biodegradable nanoparticles for drug delivery arises from their three
main basic properties. First, their small particle size facilitates their penetration into smaller
capillaries and their subsequent uptake by the cells, ensuring efficient drug accumulation at the
target sites. Secondly, their biodegradation allows sustained drug release within the target site

4

over a period of days or even weeks. Thirdly, the possibility of their surface functionalization
and modification allows active drug targeting via attachment of specific ligands.34–38,42–44
Both synthetic and natural polymers have an important role as biomedical materials for
drug delivery, yet synthetic biodegradable polymers such as poly(amides), poly(amino acids),
poly

(alkyl-a-cyano

acrylates),

poly(esters),

poly

(orthoesters),

poly(urethanes)

and

poly(acrylamides) have been increasingly used to prepare various drug-loaded devices. These
polymers are free from most of the problems commonly associated with natural polymers
(albumin, chitosan, etc.) such as immunogenicity, variability in purity across groups, complex
structure, strength inadequacy and difficulty in controlling material degradability. Among the
synthetic polymers, the thermoplastic aliphatic poly(esters) such as polylactic acid (PLA),
polyglycolic acid (PGA) and, especially PLGA, have generated tremendous interest due to their
excellent biocompatibility, biodegradability and toxicologically safe by-products.45–47
PLGA is a copolymer of lactic acid and glycolic acid. Depending on the used ratio of
lactide to glycolide, different forms of PLGA can be obtained. They are usually identified with
regard to the monomers ratio used (e.g., PLGA 75:25 identifies a copolymer whose composition
is 75% lactic acid and 25% glycolic acid). PLGA is one of the most successfully used
biodegradable polymers for the development of nano-medicines. It undergoes hydrolysis in the
body to produce the biodegradable metabolite monomers, lactic acid and glycolic acid (Figure
1.17) which are endogenous and easily metabolized by the body via kreb's cycle.40,41
The specificity of delivery using nanoparticles was initially a coincidental property,
however active targeting has now become a vital concept in therapeutic research. Active
targeting of nano- particles to particular sites in the body can be achieved using target-specific
ligands or antibodies that can be attached onto the nanoparticulate surface. These modifications
direct the drug to the specific cell for the desirable action in low doses.48
As a result, surface functionaliztion of the PZQ-loaded PLGA NPs with a specific ligands
against Schistosoma parasites may produce a more efficient form of treatment delivering the
active drug to the parasites in the host and exerting the anti- schistosomal actions over a
sustained period of time without causing undesired side effects.
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We aim at developing nano-carriers (PLGA NPs) loaded with smaller doses of the drug
(PZQ) and surface- coated with specific antibodies (Anti- Schistosoma polyclonal antibodies) for
active targeting of schistosome surface antigens.
The work in this thesis was divided into two chapters and three main studies:
1. Chapter One: Development and Optimization of PZQ-loaded PLGA Nanoparticles (Study
One)
2. Chapter Two: Development of Immuno—Nanoparticles for Active Targeting of Schistosoma
Parasites
A. Preparation of Anti-schistosomal Polyclonal Antibodies against Schistosoma Surface
Tegumental Antigens (Study Two)
B. Preparation and Characterization of PLGA Nanoparticles Surface – Modified With
Purified Anti- Schistosoma Polyclonal Antibodies (Study Three)
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Chapter One: Development and Optimization of PZQ-loaded
PLGA Nanoparticles

Section I: Methodology*
*

All materials and equipment used in this study were described in Appendix I and Appendix II respectively.

In this section, PLGA NPs either plain or PZQ-loaded were prepared. The effect of
various formulation and experimental variables on different NPs properties like size, charge,
drug encapsulation efficiency and morphological characteristics were investigated. The levels of
tested variables have been optimized to obtain NPs having the highest possible loading of PZQ
with optimum size and release profile.

I.A. Preparation of Free and PZQ-loaded PLGA Nanoparticles
PLGA NPs were prepared and PZQ was encapsulated into the NPs. As several factors
affect the characteristics of the prepared NPs as shown in Figure 1.1, the work was divided into
five main studies as shown in Figure 1.2.

I.A.1. Study I: Preliminary Study
The aim of this study was first to select the method of preparation of PZQ- loaded PLGA
NPs. Then, fabrication parameters and experimental conditions affecting the chosen method will
be optimized to be fixed and used throughout all the successive studies for NPs preparation.
Optimization of various parameters was done with respect to particle size and size distribution,
charge, drug entrapment efficiency and particle morphology.
Accordingly, the design of this study follows “One Factor at Time (OFAT)” stepwise
approach. In which, a single factor is under study in each experiment while, other factors have
fixed levels throughout all experiments. The chosen level of each investigated factor is used and
fixed throughout all successive experiments. Table 1.1 summarizes the investigated factors in
this study and the composition of the prepared formulae.
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There are several methods for preparation of PLGA NPs.49,50 As shown in Table 1.1, the
first experiment (Expt. I-1) was to select one of three of the most commonly used methods of
preparation of PLGA NPs to be further used throughout this work. Typically, the three methods
are based on preparation of an organic phase consisting of polymer (PLGA) dissolved in organic
solvent containing, or not, the drug. This organic phase is added to an aqueous phase containing
a surfactant to form an emulsion. This emulsion is broken down into nano-droplets by applying
external energy and these nano-droplets form NPs upon evaporation of the highly volatile
organic solvent. The solvent is evaporated leaving behind a colloidal suspension of PLGA NPs
in water. 41,49,51
Although the three methods have almost the same principle in NPs formation, they are
different mainly because of the different type of organic solvent used and the technique (External
Energy) applied for emulsion formation.49,50 To elucidate, if the organic solvent is completely
immiscible with the aqueous phase like dichloromethane (DCM), the method is called emulsionsolvent evaporation (ESE). While, if it is partially miscible like ethyl acetate (EA), it is known
as emulsion- solvent diffusion (ESD) method. When the solvent is miscible with the aqueous
phase, it is named as nanoprecipitation or solvent displacement technique.49,52,53 Figure 1.3 is
a schematic representation of the preparation methods.53–55

I.A.1.1. Emulsion – Solvent Evaporation (ESE) Method
Using single oil in water (o/w) emulsion – solvent evaporation (ESE) technique, formula
P1 was prepared.

53,56–58

Briefly, PZQ- loaded PLGA NPs were formed by dropwise addition of

an organic phase containing completely dissolved 50mg PZQ and 300mg PLGA in 6ml DCM to
an aqueous phase solution containing 1% w/v PVA while homogenization at 20000 rpm for 20
minutes over an ice bath. Upon emulsification, DCM was evaporated under reduced pressure
using rotavap (45oC, 14mm Hg) for 20 minutes. The formed NPs were collected by
centrifugation at 20000 rpm for 20 minutes at 4oC and washed twice. Then, NPs were resuspended in deionized water for further characterization.

I.A.1.2. Emulsion – Solvent Diffusion (ESD) Method
PZQ- loaded PLGA NPs (Formula P2) were prepared by emulsification solvent diffusion
(ESD) method. 50,59,60Briefly, the organic phase containing 50mg PZQ and 300mg PLGA in ethyl
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acetate (EA) was injected slowly to an aqueous solution of 1% w/v PVA while mixing using
homogenizer at ascending speed order from 5000, 10000 and 20000 rpm for 3 minutes each. An
excess amount of water equal to the original aqueous phase (114ml) was added slowly while
homogenization at 20000 rpm for 3 minutes. The solvent was evaporated under reduced pressure
using rotavap (60oC, 21mm Hg). Nanoparticles were purified by 20 min centrifugation at 20000
rpm at 4oC and washed twice then, re-suspended in water for further characterization.

I.A.1.3. Nanoprecipitation Method
PZQ- loaded PLGA NPs (Formula P3) were prepared by nanoprecipitation technique.
61,62

Briefly, a 6 ml organic phase (acetone) of PZQ and PLGA was slowly dropped with a

constant speed (0.5 mL/min) to a 114 ml aqueous solution of 1% w/v PVA with continuous
magnetic stirring at 800 rpm. The solvent (acetone) was evaporated at room temperature (25°C)
for 24 hours under magnetic stirring. Nanoparticles were purified by 20 min centrifugation at
20000 rpm then washed twice and re-suspended in water for further analysis.
Formulae P4 to P21 were prepared by ESE method as mentioned in Table 1.1. The aim
of Experiments I-2 to I-8 is to study the effect of various processing parameters and
experimental conditions of ESE method on the properties of NPs e.g. mean size, size
distribution, charge, drug content, drug loading and surface morphology.

I.A.2. Study II: Screening Phase
This phase is conducted to study the effect of different material characteristics on the
size, size distribution, charge and morphology of the prepared NPs. The experimental conditions
and other formulation parameters selected from the preliminary phase were used in the
preparation of all coming formulae. Table 1.2 summarizes the studied variables in this phase and
the composition of formulae S1-S10. The formulations were evaluated for particle size, size
distribution and charge.
Typically, modified single oil in water (o/w) emulsion – solvent evaporation (ESE)
technique was used for the preparation of PLGA nanoparticles. Briefly, a specified volume of the
organic solvent dichloromethane (DCM) containing completely dissolved PLGA was slowly
poured into aqueous poly vinyl alcohol (PVA) solution and leucine (0.01%, w/v) while mixing in
homogenizer at ascending speed order from 5000, 10000 and 20000 rpm for 3 minutes each.
9

The resulting emulsion was sonicated using a probe sonicator. During homogenization and
sonication, the whole system was placed in an ice bath to prevent any loss of the oil phase due to
evaporation. The organic phase was evaporated on a magnetic stirrer under atmospheric
conditions till complete evaporation of DCM accompanied by the formation of colloidal
suspension of PLGA nanoparticles (NPs). The nanoparticles were recovered by 30 min
centrifugation at 11,000 rpm then washed twice in order to remove the adsorbed PZQ and any
excess surfactant from the surface of NPs. The washing solutions were eliminated by a further
centrifugation as described previously. The purified nanoparticles were either freshly used for
further investigation or re-suspended in water containing 0.2% w/v sucrose (lyoprotectant) and
lyophilized using a freeze-drying system yielding powdered nanoparticles which were stored in
desiccator to be used for further analysis. All nanoparticle suspensions were prepared in
triplicate.

I.A.3. Study III: Validation Phase I
This study was conducted to validate the selected variables from both the preliminary and
screening phases. The validation was performed using both PLGA 50:50 and PLGA 75:25 as
shown in Table 1.3 to see the their effect on drug encapsulation and drug loading.
PZQ- loaded PLGA NPs were prepared by the same method mentioned in section I.A.2.
However, PZQ was dissolved first via vortexing in the specified volume of the organic solvent
dichloromethane (DCM), containing PLGA. A non-medicated preparation (Blank) was prepared
to study the effect of drug on nanoparticles character and find the interference from nanoparticles
components at drug wavelength.

I.A.4. Study IV: Optimization Phase
This phase was required to be conducted to optimize the drug encapsulation efficiency
and drug loading. Various parameters that might affect the PZQ encapsulation into PLGA NPs
were studied using OFAT approach. All the experiments are conducted by varying one of the
parameters while keeping all the other parameters at a set of standard conditions as shown in
Table 1.4. NPs were prepared as mentioned previously and illustrated in Figure 1.4.58,63 The
formulations were optimized on the basis of size, size distribution, charge, entrapment efficiency
and drug loading.
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I.A.5. Study V: Validation Phase II
All selected factors combined were validated to reach the optimized formulae with the
highest PZQ encapsulation efficiency and loading into PLGA NPs with optimum size and size
distribution. Also, the effect of initial drug weight on NPs properties was studied as shown in
Table 1.5.

I.B. Characterization of Blank and PZQ- Loaded PLGA Nanoparticles
The method used for preparation of NPs was optimized with respect to various
fabrication parameters and experimental conditions over five successive studies as described
earlier. The prepared NPs were characterized on the basis of particle size, size distribution,
charge, drug entrapment efficiency and drug loading till the formula with the highest possible
drug encapsulation efficiency and drug loading with optimum size and homogenous size
distribution was obtained. In addition to that, the optimized formula was further evaluated to
study the PZQ release behavior from PLGA NPs, the NPs morphology using scanning electron
microscopy (SEM) and atomic force microscopy (AFM), and the physical compatibility between
NPs components with confirmation of PZQ encapsulation into PLGA NPs using differential
scanning calorimetry (DSC) and Fourier-Transform infrared spectroscopy (FTIR).

I.B.1. Particle Size Determination and Particle Size Distribution
The hydrodynamic diameters (Z-Average) of NPs were determined by photon correlation
spectroscopy (PCS) based on quasi-elastic or dynamic light scattering (DLS) using a particle size
analyzer (Zetasizer). This technique yields the particle mean particle diameter and the
polydispersity index (PDI); which is a dimensionless measure for the broadness of the particle
size distribution.

64–66

Briefly, the freshly prepared and purified suspension of NPs was a 1/100

(v/v) diluted in MilliQ water. However, for lyophilized NPs, 1mg NPs were suspended in 5ml
deionized water and shaken to ensure uniform distribution. Size measurements were performed
in disposable cuvettes at a scattering angle of 90o and at a temperature of 25oC. For statistical
analysis all samples were measured in triplicate and the average values and standard deviation of
the measurements were calculated.
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I.B.2. Zeta potential (ζ) Measurements
Surface Charge (ζ potential) of NPs was analyzed by laser Doppler anemometry (LDA)
using the same instrument (Zetasizer) and the protocol mentioned above (section I.B.1). The NPs
suspension was 100-fold diluted in deionized water and measured in a capillary cell (detector
angle 90°, at 25°C, wavelength 633 nm). Measurements were carried out in triplicate. Results are
expressed as mean ±SD.56,67,68

I.B.3. Quantitative determination of PZQ, Drug Encapsulation Efficiency
and Drug Loading
I.B.3.1. Quantitative Analysis of PZQ
Several procedures have been developed for the quantitative determination of PZQ.
These

procedures

include

high

performance

liquid

chromatography

(HPLC),

gas

chromatography (GC), spectrophotometry and colorimetry. 56,69 In this study, quantitative HPLC
of PZQ was performed using Agilent 1260 Infinity Quaternary LC with a Diode Array Detector
DAD (set at 262 nm) and Agilent Standard Autosampler with a 100 μL loop. Chromatographic
separation was accomplished using a reversed phase Agilant Zorbax SB-C18 column (150 mm x
4.6 mm id., 5 μm particle size). The flow rate was isocratic at 1 mL/min. The mobile phase was
prepared by mixing acetonitrile with water 60:40 (% v/v).The UV detector was set at 262 nm.
The HPLC system was operated at (30 ± 1 °C). The mobile phase was filtered through a
membrane filter (0.45 μm X 47 mm) and degassed through Agilent 1260 infinity quaternary
pump. The analysis required less than 3.2 min.
Stock solution of PZQ standard (500μg/mL) in acetonitrile: water (60:40) was freshly
prepared accurately weighing 50 mg PZQ reference substance, transferring to a 100 mL
volumetric flask followed by addition of mobile phase to make up the volume. The working
solutions were prepared by diluting the stock solution in the mobile phase to prepare a set of
calibration solutions of concentration ranging between 2 and 15µg/ml. A calibration curve was
constructed by plotting the area under the curve (AUC) and the concentration of the drug in
μg/mL. The linear regression equation was calculated. All determinations were conducted in
triplicate.
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The accuracy, precision of the assay and linearity of the calibration curve were
determined for intra- and inter-day on three different days. The precision was expressed as the
percent coefficient of variation (CV %) of each curve.

I.B.3.2. Drug Entrapment Efficiency and Drug Loading
The amount of PZQ entrapped in the nanoparticles was determined by HPLC in triplicate
under the same conditions as described above (Section I.B.3.1).

56

The method adopted for

estimating the entrapment efficiency was a direct method via drug extraction from NPs.

70

Definite amount of the precipitated NPs (1mg) were added to excess volume of methanol (10
mL). The solvent containing the NPs was vigorously stirred over shaker incubator at 300rpm for
48 hours at RT in order to completely extract out the drug. After eventual dilutions in the mobile
phase, the concentration of the extracted drug measured assayed using the above HPLC method
(UV detection set at 262 nm, a reversed phase C18 column (150 mm x 4.6 mm id., 5μm particle
size) was used, the mobile phase consisted of a mixture of acetonitrile: water (3:2 v/v) and the
flow rate was set at l mL/min) against a blank formula. The solutions were previously filtered
using a membrane filter (pore size 0.45 μm X 47 mm). All measurements were done in triplicate.
The encapsulation efficiency EE (%) was calculated according to the following equation:
EE% = (Actual Drug Weight in NPs / Initial Drug Weight) X 100
The drug loading (DL) was calculated according to the following equation:
DL% = (Actual Drug Weight in NPs / Initial Drug and Polymer Weights) X 100
Also, indirect estimation of PZQ concentration in supernatant after NPs purification (Indirect
Method) was done to confirm the complete extraction of the drug from NPs. In this case, the
encapsulation efficiency was calculated as follows:
EE% = [(Initial Drug Weight — Measured Drug Weight in NPs) / Initial Drug Weight] X 100

I.B.4. In Vitro Release Study
The in vitro drug release profile of entrapped PZQ from PLGA NPs was studied by
dialysis bag diffusion technique.

71,72

Each dialysis bag (Cellulose membrane molecular weight

cut-off: 12 kDa) was loaded with an accurately weighed amount of lyophilized NPs of optimized
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preparation (VII4) equivalent to 500µg of drug. The particles were suspended in 2 mL of PBS
(pH = 7.4). The dialysis bag was then immersed in 20 ml of release medium PBS (pH = 7.4)
containing 0.02 % sodium azide as preservative at 37±1 °C and was continuously stirred on a
shaker incubator at 100 rpm/min. At predetermined time intervals, aliquots of 500µL were
withdrawn and replaced with the same volume of fresh dialyzing medium and the withdrawn
samples were assayed for drug content against the blank using HPLC. The obtained values were
corrected for the dilution used during the sampling. Experiment was performed in triplicates.
Drug release data were expressed as the percentage of the cumulative amount of drug release.

I.B.5. Thermal Analysis Using Differential Scanning Calorimetry “DSC”
The physical state of the PZQ encapsulated in PLGA NPs was characterized using a
differential scanning calorimetric (DSC) thermogram analysis (Perkins Elmer Differential
Scanning Calorimeter). Samples of drug, polymer, SAA, physical mixture of drug and polymer,
physical mixture of drug and SAA and freeze dried drug-loaded NPs were tested. Each sample
(10mg) was sealed separately in a standard aluminum pan, the samples were purged in DSC with
pure dry nitrogen set at a flow rate of 20 ml/ min, the temperature speed was set at 10oC/min, and
the heat flow was recorded from 30 to 350oC. Indium was used as the standard reference material
to calibrate the temperature and energy scales of the DSC instrument.65,68,73

I.B.6. Spectral Analysis Using Fourier-Transform Infrared Spectroscopy
“FTIR”
The Fourier transform infrared (FTIR) spectra for PZQ, PLGA, PVA, physical mixture of
drug and polymer, physical mixture of drug and SAA and freeze dried drug-loaded NPs were
obtained using FTIR spectrophotometer for characterizing the chemical integrity of PZQ inside
PLGA NPs. Briefly, the samples (3mg each) were pressed with potassium bromide (KBr) to
make a pellet by applying a pressure of 300 kg/cm2 before obtaining their IR absorption spectra.
The spectra were detected in KBr discs over a range of 4000-400 cm-1. The detector was purged
carefully by clean dry helium gas to increase the signal level and reduce moisture.68,74

I.B.7. Particle Morphology
The surface morphology of the prepared NPs was examined as follows:
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I.B.7.1. Optical Microscope
For microscopic analysis, a sample of the prepared NPs dispersion was placed on a
microscope slide, diluted with deionized water, examined using Leica optical microscope at a
magnification of 40X and photographed for morphological evaluation.

I.B.7.2. Scanning Electron Microscopy
The surface morphology of nanoparticles was characterized by scanning electron
microscopy SEM. Briefly, the NPs samples for SEM analysis were prepared either by drying a
drop of nanoparticle freshly prepared suspension on a metal stub as non-aggregated particles or
by affixing the NPs lyophilized powder to stubs using double-sided carbon tape. Then, the NPs
were sputtered with a thin layer of gold using a current of 40 mA for 25 seconds under an argon
atmosphere in a high-vacuum evaporator to make them conductive electron microscopic
scanning. Observation was performed at an accelerating voltage of 10–30 kV. 66,73

I.B.7.3. Atomic Force Microscopy
The NPs samples were examined for their shape and morphology and their surface
properties were evaluated using atomic force microscope (AFM) “Vecco Atomic Force
Microscope”. The samples were prepared separately on sample holders (Silicon Wafers). On
each holder, one drop of sample suspension was dried as non-aggregated particles and
examined.75,76

I.C. Statistical Analysis
All experiments were carried out three times, independently. Results are expressed as
mean ± standard deviation (SD). Significant statistical differences between groups were
examined by applying Student's t-test for two groups’ comparison and one-way analysis of
variance (ANOVA) for three or more groups. The statistical significance level (P value) was set
at ≤0.05. Statistical analysis was done to all data obtained for all NPs formulae. All tests were
calculated using the software GraphPad Prism Software Version 6, San Diego, CA.
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Section II: Results and Discussion
In this section, PLGA NPs were prepared either un-loaded or PZQ- loaded using three
different methods at the beginning: ESE method, ESD technique and nanoprecipitation method
(Figure 1.3). Single (O/W) ESE method was selected (Figure 1.4).58,63 The effect of several
formulation parameters and experimental conditions affecting this technique was investigated.
Their levels were selected and optimized till achieving the optimum formula with the optimized
size (200.8 ± 4.02 nm) with homogenous size distribution (PDI = 0.13 ± 0.08) and the highest
encapsulation efficiency and drug loading (EE% = 94.19% ± 3.47, DL% = 47.095% ± 3.47). The
optimized formula was further characterized for their shape and surface morphology using SEM
and AFM. They were also characterized for their physicochemical properties using DSC and
FTIR. In addition, PZQ release behavior from PLGA NPs was assessed using the dialysis bag
diffusion technique.

II.A. Quantitative Analysis of Praziquantel
Before preparation of PZQ- loaded PLGA NPs and to be able for their characterization, a
method for quantitation of PZQ should be established and a calibration curve should be
constructed to quantify the entrapped PZQ in PLGA matrix, calculate the drug loading and
assess the cumulative PZQ release percent from NPs.
As mentioned in the methodology chapter, a HPLC method for determination of PZQ
was used as described in the United States Pharmacopeia (USP XXVI) using as mobile phase a
mixture of acetonitrile and water in the proportion of 60:40. It is worth mentioning that although
the UV detector was set at 210 nm in the protocol mentioned in the US pharmacopeia, the UV
detector was set at 262 nm in this method. This is because the pharmacopeia method was
established for PZQ determination in tablets.

77,78

However, in the development of new dosage

forms for drugs, special care must be taken in the selection of the adequate wavelength because
other substances present in the formulation used as adjuvants can be absorbed in the same
wavelength of the drug, interfering this in the results of the analysis. In the case of PZQ, the
wavelength of 210 nm shows a high absorptivity, but in some cases it is not selective for its
quantification because it depends on the excipients being used in the formulation. Some
polymers, mainly polyesters, are absorbed in a wavelength of 210 nm, and as these substances
are very much used in solid dosage forms, other wavelength must be selected. As validated in
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many previous studies, a HPLC method for determination of PZQ which allow a better
selectivity in the presence of polyesters, using a UV detector set a 262 nm.56,68,78
In this study, linearity of the standard calibration curve was investigated (Figure 1.5) and
the ideal concentration range to work with was selected (Table 1.6). The interval showed the
desired linearity. The analytical curve for PZQ in a concentration range from 2 to15 μg/mL was
linear presenting correlation coefficient (R) of 0.999 and R2 of 0.999. The linear regression
equation was found to be:
y = 6.3111 x + 0.2549
Where y is the area under the curve (AUC) and x is the concentration of standard in μg/mL.
The accuracy and precision of the assay was also determined. The intra-day assay
coefficients of variation (CV %) for PZQ at 12 μg/mL (n=10) in the first day was found to be
1.86%. In the second day, it was 1.28% and in the third day, it was 2.16%. The inter-day assay
was assessed on 3 individual days, the CV % was 1.77% at 12 μg/mL. These data show a
remarkable degree of precision and reproducibility of the method, both within runs and betweenruns.
The retention time repeatability during the precision studies was found to be good to all
solutions. The retention times (tR) of the PZQ reference substance was 3.2 min as shown in the
chromatogram of PZQ reference standard (Figure 1.6). The limit of detection of PZQ was
approximately 1µg/mL. The limit of quantification was set at 2µg/mL being the lowest
concentration used in the constructions of the standard curve. Thus, this HPLC assay was
considerably simple, precise and sensitive for PZQ quantification especially that PLGA polymer
did not interfere with the reading of PZQ at the selected wavelength (262nm). PlGA was
separated chromatographically at earlier retention time (1.2 minutes) as shown in Figure 1.6b.

II.B. Preparation and Evaluation of Blank and PZQ-loaded PLGA NPs
As explained above, five main studies (Figure 1.2) were conducted to select the optimum
or best level of each studied factor affecting the prepared NPs properties prepared by the single
ESE method (Figure 1.1). The PLGA NPs either plain or medicated were optimized with regards
to their mean diameter, size distribution, charge, drug entrapment efficiency and drug loading.
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They are also characterized for their surface morphology, thermal behavior, chemical integrity
and drug release behavior. The results of each study will be discussed in this section.

II.B.1. Study I: Preliminary Phase
The first objective of this study was to choose the method of preparation of NPs loaded
with PZQ (Expt. I-1). Then, several process parameters were varied to identify their influence
mainly on the particle size and entrapment efficiency keeping the other parameters constant as
shown in Table 1.1. Table 1.7 and Figure 1.7 summarize the results of the eight different
experiments (Expt. I-1 to Expt. I-8) conducted in this study. The selected level of each studied
parameter was highlighted in yellow as shown in Table 1.1.

The main findings will be

highlighted and discussed as follow:
In Expt. I-1, three methods of preparation were used for formulation of PZQ- loaded
PLGA NPs to study the effect of organic solvent type. Single (O/W) ESE method using DCM
as organic solvent (Formula P1), ESD technique using the organic solvent EA (Formula P2) and
nanoprecipitation method using acetone (Formula P3) were conducted.
Concerning formula P3 prepared using acetone, it had the smallest particle diameter
(96.71± 4.8nm) which is significantly lower than the particle size of both P1 and P2 (p-value
<0.0001). However, its encapsulation efficiency is much more less than that of both formulae P1
and P2 (2.7 ± 1.13% in comparison to 4.2±0.85 and 4.15±0.99%, respectively). This could be
due to the rapid formation of particles not allowing enough time for encapsulating more PZQ
during the emulsification step; as the solvent used in nanoprecipitation method is partially
miscible with aqueous phase leading to a decrease in the interfacial tension between the oil phase
and aqueous phase with increasing its diffusion into the aqueous phase causing interfacial
turbulence. This perturbation further results in a larger interface area between the oil droplets and
aqueous medium and creates extremely fine nano- droplets which result in the formation of small
sized nanoparticles rapidly.

79

On the other hand, formula P2 prepared using EA as organic

solvent showed the largest size measuring 341.83± 9.4nm which is significantly higher than that
of formula P1 (281.3±3.98nm).
The results also revealed that all the prepared NPs are negatively charged. This could be
due to the presence of carboxylic groups on the surface of NPs especially that the PLGA selected
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for NPs formulation was uncapped “acid-terminated” to enable its surface functionalization as
will be explained in Chapter Two.80 It was also noticed that the used levels of various parameters
for preparation of PLGA NPs need further optimization to improve the particles’ size
distribution, reduce its diameter and increase the very low obtained EE% and DL%.
As a result, ESE method was used for the further preparation of PZQ- loaded PLGA NPs
and the variables affecting it were studied to choose their optimum levels. As mentioned earlier,
ESE technique has five successive phases: O/ W emulsification, DCM evaporation, NPs
purification and washing, Pellet resuspension and lyophilization. The effect of variables
controlling each phase was studied (Expt. I-2 to I-8) and the obtained results were shown in
Table 1.7 and illustrated in Figure 1.7.
It was noticed from Expt. I-1 that the yield of formula P1 was noticeably decreased after
using rotavap for DCM evaporation to represent about 60.5± 4.1% of the initial added weights of
polymer and drug. As a result, evaporation of the organic solvent under atmospheric conditions
using magnetic stirrer (Formula P5) was compared to its evaporation under reduced pressure
using rotating evaporator (Formula P4). Effect of type of evaporation technique was studied in
Expt. I-2.
Comparing the two evaporation methods represented by formulae P4 and P5
respectively, there were no statistically significant differences in the physical properties of the
prepared NPs. However, the EE% is decreased from 4.2±0.85% to 2.13±1.45%. But, this might
be due to the long evaporation time on stirrer for about 12hr. Yet, the yield of NPs increased to
reach 93.74 ± 2.33% in case of evaporation under atmospheric conditions.
Due to the results obtained from Expt. I-2, the effect of the duration of evaporation on
NPs properties especially EE% was studied in Expt. I-3. Four time durations (2, 4, 6 and 12
hours) were tested. It was revealed that by reducing the time allowed for DCM evaporation, the
EE% and DL% of PZQ inside PLGA NPs increases; and interestingly, the particles size
decreases.
In a trial to increase the amount of the entrapped drug in NPs, the effect of
centrifugation conditions for purification of formulated NPs and washing of excess SAA and
un-entrapped PZQ from the surface of NPs was investigated (Expt. I-4). Formula P11 showed
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slight decrease in particle size (241.1±2.67nm) in comparison with 249.6± 3.33nm for formula
P10. It also showed better size distribution (0.38±0.13 instead of 0.52±0.21) and slightly higher
EE%. It was also noticed that the ultra- speed of centrifugation caused the aggregation of
precipitated NPs and more difficult re-dispersion of the purified NPs pellet for further wash or
use and it was taking long time vortexing.
The effect of adding 0.01% L-leucine as antiaggregant to the external aqueous phase
in order to facilitate the NPs dispersion in ionized water after centrifugation was therefore tested
(Expt. I-5). Formula P13 containing L-leucine showed lower PDI (0.29±0.11) than formula P12
(0.38±0.13).
The external energy applied for size reduction of the formed droplets in the emulsion to
reach the nano- size could be of different sources: high speed homogenization, ultra- sonication
or both. The Effect of emulsification technique was studied in Expt. I-6. Formula P16
emulsified by homogenization followed by sonication reduced the size of nano-droplets in the
emulsion producing homogenously distributed NPs population (0.07±0.09) when compared to
formula P14 (0.29±0.11) and P15 (0.583±0.155).
Then, the effect of sonication duration was also studied Expt. I-7. In In this experiment,
the effect of decreasing the sonication time on particles mean diameter, size distribution and the
amount of drug encapsulated into NPs was investigated. By reducing the time duration of
sonication, increase in the particles diameter and PDI was obviously noticed. The NPs size
increased to 280.3±3.98nm in case of 5 minutes sonication (Formula P19) compared to
246.63±3.86nm and 222.97±2.09nm for formulae P18 (10 minutes) and P17 (20 minutes)
respectively.
The last experiment in this phase was to study the effect of freeze drying
(Lyophilization) of purified NPs on the various physical characteristics of PZQ- loaded PLGA
NPs (Expt. I-8). No significant difference on characterization results were observed as shown by
formulae P20 and P21 in Table 1.7. Similar findings were reported in previous studies. 65
Generally, in all experiments in this study, no significant effect was noticed on surface
charge of NPs. Zetapotential of all formulae ranged from -24 mV to -28 mV. The high negative
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charge was due to the negativity of the used polymer in this study (Low molecular weight,
uncapped PLGA 75:25). This could be explained by that, during preparation of PLGA NPs, oil
droplets were formed in the aqueous medium consisting of the PLGA polymer encapsulating
PZQ. This causes the ionizable carboxyl groups of the polymer to orient themselves towards the
surface exerting the negative charge on the surface, while the hydrophobic portions formed the
core of the polymerizing NPs matrix. This could be of benefit for the produced emulsion stability
as the classic colloidal theory states that electrostatic forces at particle surfaces can cause
repulsion and prevent aggregation by virtue of fewer collisions and ionic attractions. 81
Also, there was no significant effect of the studied factors on PZQ encapsulation
efficiency and in turn on its loading inside the polymer matrix. However, the resulted EE% and
DL% were surprisingly extremely low (less than 5% and less than 1% respectively). This might
be due to two factors; the first one is the low molecular weight of the used PLGA 75:25 (17000
Da) and the second one is its high hydrophobicity. It is worth mentioning that it was expected
that such polymer properties should result in higher drug loading; since, PZQ was known to be
highly hydrophobic in nature. However, by referring to the solubility properties of the drug 77, it
was found that it has very slight solubility in aqueous solutions (0.22mg/ml). Accordingly, a less
hydrophilic polymer with higher molecular weight (PLGA 50:50, 44000 Da) was used in
validation phase I to study its effect on PZQ encapsulation efficiency and loading%.

II.B.2. Study II: Screening Phase
In the present study, the effect of variable parameters and conditions on the formulation
of PLGA NPs loaded with PZQ was investigated: the PLGA concentration, the DCM volume
and surfactant type in the formulation. Only one parameter was changed in each series of
experiments. The impact of formulation variables were investigated mainly on size distribution,
polydispersity and the surface charge of NPs. Three experiments were conducted in this phase.
The studied variables and the obtained responses were summarized in Table 1.8 and graphed in
Figure 1.8.
Effect of Polymer Concentration was evaluated in Expt. II-1. Decreasing the PLGA
polymer (% w/v) from 5% (Formula S3) to 2.5% (S2) and 1% (S1), though resulted in slight
decrease in particle size, it had negative effect of size distribution as the PDI increased in case of
formula S1 to be 0.38±0.1 instead of 0.28±0.08 and 0.09±0.02 in case of formulae S2 and S3
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respectively. These results run with that published in previous studies which revealed that
increasing the amount of polymer resulted in an increase in size of the formulation. 70,82,83
In addition, the effect of organic solvent % was tested in Expt. II-2. While decreasing
the volume of DCM resulted in significant increase in the particle size to be 290.3±3.75nm in
case of 1% DCM (S4) compared to 225.77±0.92nm when 5% (S6) was used for preparation of
PLGA NPs (p- value < 0.0001). It also increased the PDI to be 0.49±0.1.
Four types of SAA were used for formulation of PLGA NPs to evaluate the effect of
surfactant type on NPs properties (Expt. II-3). Tween-80 resulted in statistically larger NPs
size with heterogeneous size distribution of particles, Formula S8 (545.97±7.3nm) compared to
formula S10 prepared using PVA (p- value < 0.0001). PVA, a non-ionic amphiphilic copolymer
locates at the interface between particle surface and the aqueous medium during formulation.
The hydrophobic segments of PVA penetrate and are entrapped in the polymeric matrix while
the hydrophilic segments reduce interfacial tension.

81,85

Both poloxamer 188 (S9) and

poloxamer 407 (S7) also increased the size and PDI of PLGA NPs significantly.

II.B.3. Study III: Validation Phase I
The selected levels of all studied variables in both studies I (preliminary phase) and II
were collectively validated to see their simultaneous effect on NPs properties either as unloaded
(Formula VI1) or PZQ- loaded (Formula VI2). Also, as the entrapped drug amount was still
particularly low, PLGA having different characteristics (Higher molecular weight, uncapped
PLGA 50:50) (Table 1.3) was used for the preparation of formulae (VI3 and VI4). Results were
demonstrated in Table 1.9 and Figure 1.9. As shown, formula VI4 prepared using PLGA 50:50
showed significantly higher encapsulation efficiency than formula VI2. Consequently, PLGA
50:50 was used for preparation of NPs in all the coming studies.

II.B.4. Study IV: Optimization Phase
The objective of this study was mainly to maximize the EE% and DL% while optimizing
size, polydispersity and surface charge. In this study, PLGA NPs loaded with PZQ were
formulated by emulsion solvent evaporation technique. The effect of various formulation
variables as mentioned in Table 1.4 were assessed systematically to obtain higher encapsulation
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efficiency and drug loading and to minimize the NPs size. The impact of these variables on
different NPs characteristics were recorded in Table 1.10 and Figure 1.10.
As illustrated, Expt. IV-1 tested the effect of PVA concentration. Decreasing the
PVA%, although increased the particle size slightly, it increased the EE% and DL% by more
than the double. Using 0.5% PVA (Formula O1) produced more homogenously distributed NPs
(PDI = 0.04± 0.03) with PZQ EE% and DL% equal to 10.39±1.65% and 1.47±1.65%,
respectively. This finding was in agreement with ones from other studies.42,56,86
As most of the parameters affecting the properties of PLGA NPs prepared by ESE
method were studied and the EE% and DL% were still low. This was believed, unexpectedly, to
be due to the very slight solubility of PZQ in the external aqueous phase. Effect of salt addition
to external aqueous phase was studied in Expt. IV-2. Addition of salt to the external phase,
which is completely soluble in the aqueous phase, was believed to reduce the solubility of the
drug and, in turn, increase its encapsulation inside the PLGA polymer. The effect of two salts
was assessed, sodium chloride and ammonium sulphate. In both types, the PZQ EE% increased
significantly to be 27.22±1.17% and 26.33±1 for NaCl (Formula O5) and (NH4)2SO4 (Formula
O6), respectively. However, no significant difference between their effects on the physical
properties of PLGA NPs, the physical stability of the O/W emulsion produced using (NH 4)2SO4
is much better than the one prepared by NaCl.
Based on the results obtained from (Expt. IV-2), higher concentrations of (NH4)2SO4
were used to evaluate the effect of salt concentration on PLGA NPs properties (Expt. IV-3).
Interestingly, 20% of salt in the external aqueous phase (Formula O9) increased the EE%
significantly to reach 99.9±5% and the 10% salt concentration (Formula O8) resulted in EE%
equals to 65.38±1.58%. Unfortunately, both concentrations affected the NPs size and distribution
negatively. The size and PDI of formula O8 were 610.1±6.56nm and 0.58±0.07, respectively.
While, the size of formula O9 was 608.2±4.7nm and PDI equals to 0.58±0.12. This could be due
to a decrease in stability of the prepared emulsion as a result of reduced electrostatic repulsions
upon addition of salts to the external aqueous phase causing flocculation of the particles due to
the presence of positive Na+ and NH4+ ions in the external phase. Therefore, 5% (NH4)2SO4 was
selected and further optimization was required.
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The effect of changing D:P was studied in Expt. IV-4. Five ratios were tested
ranging from 1:1 to 1:10. It was expected that increasing the polymer would result in higher
EE%. Surprisingly, 1:10 (Formula O14), PZQ to PLGA ratio, resulted in significant decrease in
EE% (3.65±5.43%) and DL% (0.331±5.43%) with sight increase in particles size
(237.2±2.66nm). Interestingly, the 1:1 ratio (Formula O10) produced NPs with the highest EE%
(37.9±2.1%) and DL% (12.63±2.1%) with slight decrease in size (193.6±1.89nm) and PDI
(0.09±0.01). These findings were on the contrary of previously reported data that declared that
the highest the polymer to drug ratio, the more entrapped drug would be.

53,70

The obtained

results might indicate that the prepared PZQ- loaded PLGA NPs were in form of nanocapsules
rather than nanospheres. Figure 1.11 illustrated the difference in their structures; smaller amount
of the polymer was required to encapsulate PZQ inside it rather than a large amount of PLGA
where the drug molecules were being dispersed within. 53

II.B.5. Study V: Validation Phase II
Selected levels of all tested variables in the four previous studies were validated for the
preparation of the optimized formula either as blank or medicated PLGA NPs as shown in Table
1.5. Also, the effect of initial drug weight first dissolved in DCM was studied using two levels
either 50mg or 100mg PZQ (Expt. V-1 and V-2). The results obtained upon characterization
were shown in Table 1.11 and illustrated in Figure 1.12. It was clear that combining all the
selected levels together resulted in further increase in EE% and DL%. Formula VII2 increased
the PZQ encapsulation to be 77.16±2.05% with drug loading equals to 38.59±2.05%. Further
increase in EE% and DL% was achieved when the initial drug weight used for preparation of
NPs was increased to be 100mg instead of 50mg. Formula VII4 showed NPs with about
94.19±3.46% of encapsulated PZQ which was equivalent to 47.095±3.46% of PZQ loading.
Consequently, formula VII4 was selected as the optimized formula for further characterization
and experimentation. A second formula (VII8) was suggested as the second optimized formula.
As shown in Table I11, the blank formulae (VII1, VII3, VII5 and VII7) were slightly smaller in
size than the medicated formulations.

II.C. Further Characterization of Selected Optimum Formulation
By the optimization of formulation process, the PZQ- loaded PLGA NPs optimum
formula VII4 were obtained in submicron size from 200.8 ± 4.02 nm and monodispersed (PDI
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0.13 ±0.08) . The encapsulation efficiency of nanoparticles loaded with PZQ was 94.19 ± 3.46 %
and drug loading equals to 47.095 ±3.46%. This selected formula was further observed by SEM
and AFM. NPs presented smooth surface and spherical shape. Also, their physical properties and
thermal behavior was characterized using DSC and their chemical integrity was evaluated using
FTIR. Furthermore, lyophilized NPs was evaluated for in vitro release in phosphate buffered
saline (pH = 7.4) by using dialysis bag diffusion technique.

II.C.1. Thermal Analysis Using Differential Scanning Calorimetry “DSC”
To further assess possible interactions between PZQ and the polymer, DSC analysis was
performed on pure PZQ and PZQ- loaded nanoparticles. Figure 1.13 shows DSC thermogram
that helps to know the nature of the encapsulated drug in the NPs as the physical state of the drug
in the polymeric matrix could influence its release characteristics.
It was observed that the endothermic peak of PLGA is at 54oC as PLGA exhibited a glass
transition temperature (Tg) at 54oC. The endothermic peak of pure PZQ was found
approximately at 136oC. This characteristic peak was not observed in PZQ- loaded NPs. The
absence of detectable crystalline domains of PZQ in drug loaded NPs clearly indicates that PZQ
encapsulated in NPs is in the amorphous or disordered-crystalline phase or in the solid-state
solubilized form in the polymeric matrix. This disordered- crystalline phase of PZQ inside the
polymeric matrix helps in sustained release of the drug from the NPs. Thermogram of the
physical mixtures of PLGA and PZQ (1:1) or PVA and PZQ (1:1) are superimposition of the
curves of their singles. Absence of the PVA characteristic peak from the curve of PZQ- loaded
PLGA NPs confirms its thorough washing while purification of NPs.68,87,88

II.C.2. Spectral Analysis Using Fourier-Transform Infrared Spectroscopy “FTIR”
FTIR uses infrared radiation to determine the chemical functionalities present in a
sample. When an infrared (IR) beam hits a sample, chemical bonds stretch, contract, and bend,
causing it to absorb IR radiation in a defined wavenumber. The resulting plot is of absorbance
(or transmittance) versus wavenumber as shown in Figure 1.14. As it can be seen, free PLGA
ester and acid bonds absorption peaks can be observed in 1760 cm-1 and 1713cm-1. While, free
PZQ’s carbonyl functional groups was stretching at 1630cm-1. Another stretching vibration
caused by – C—N appeared from 1350 – 1000cm-1. Figure 1.15 shows the chemical structure of
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PZQ. The physical mixture and NPs showed an overlap between the two infrared curves of
PLGA and PZQ. This induced that there’s no strong chemical interaction between PLGA and
PZQ. 68,74,84,89

II.C.3. In Vitro Release Study
Efficient release of encapsulated drug from NPs is an important parameter for developing
successful formulations. The obtained results in Table 1.12 and Figure 1.16 clarified the release
pattern of PZQ from PLGA NPs (Optimum Formula VII4) compared to PZQ alone (Control)
over 35 days. It was evident that more than 90% of PZQ powder was dissolved and diffused
through the dialysis membrane in the first 24 hours (93.77±2.02%) compared to only
54.21±2.88% in case of PZQ- loaded PLGA NPs (Initial burst release). The high initial burst
release could be due to easy diffusion of drug molecules through the polymeric matrix at the
beginning followed by a sustained release of the encapsulated drug. This finding was further
supported by the thermal behavior of PZQ- loaded PLGA NPs studied using DSC. As previously
mentioned, the presence of the drug in amorphous or in disordered-crystalline phase would help
it to diffuse through the small pores of the NPs easier than if the drug was in crystalline form
(large sized molecules) inside the particles. 48
Then, during the first 2 weeks of the study, slow sustained release of PZQ was observed.
The curve was almost a plateau with the release of about 62.46±2.74%. This might be due to
diffusion of the drug through PLGA polymer matrix. Especially that the pH of the release
medium was still ranging from 7.2 to 7.4 which means that PLGA was not yet started to degrade
to its monomers, lactic and glycolic acids (Figure 1.17).53,90,91 However, after 14 days, sustained
release was continued though on a higher rate. By measuring the pH of the release medium, it
started to decrease till reaching pH equivalent to 6.1 at the end of study duration. This means that
the release of PZQ was started to be due to the degradation of the PLGA polymer in a very slow
rate as well. The amount released by the end of the 35 days was 79.82±2.45%; this confirms that
sustained release of PZQ from PLGA NPs was successfully achieved.

II.C.4. Particle Morphology
Morphology of prepared PLGA NPs was characterized using different techniques: optical
microscope, scanning electron microscopy (SEM) and atomic force microscopy (AFM).
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II.C.4.1. Optical Microscope
Figure 1.18 shows PZQ- loaded PLGA NPS prepared by ESE using optimum levels
(Formula VII4). Spherical shape and homogenous particle size distribution were evident.

II.C.4.2. Scanning Electron Microscopy
When a sample is bombarded with electrons, it emits secondary electrons and X-rays.
The intensity of the secondary electrons is detected to generate a high resolution three
dimensional surface image. X-rays can be detected to conduct elemental analysis. SEM is not as
surface sensitive as other techniques and non- conducting polymers must be sputter-coated prior
to analysis. Nevertheless, it is one of the more widely available tools in surface analysis, and it is
thus often used to measure surface topography.92 Figure 1.19 is a scanning electron micrograph
of formula VII4 showing spherical NPs with smooth surface. Figure 1.20 shows scanning
electron micrographs of various prepared formulae.

II.C.4.3. Atomic Force Microscopy
AFM has sub-nanometer resolution. In AFM, a tip attached to a flexible cantilever moves
across the sample surface to measure surface morphology on an atomic scale. The change in
surface height is then measured by the location of the reflected laser beam in the quadrant photodetector, and surface topography is generated.93 Figure 1.21 shows PLGA NPs of formula VII4
with smooth surface and spherical morphology.
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Chapter Two: Development of Immuno—Nanoparticles for
Active Targeting of Schistosoma Parasites

Section I: Methodology*
*

All materials and equipment used in this study were described in Appendix I and Appendix II respectively

The aim of the work presented in this chapter is to prepare antibody- coated PLGA NPs
for active targeting of Schistosoma parasites. To achieve the set objective, the work was divided
to two main sections. The first one is the production, purification and characterization of
polyclonal antibodies “pAb” specific against schistosomes’ surface antigens “sAg”. While the
second study was the surface functionalization and coating of the optimized PZQ-loaded PLGA
NPs formula (VII4), prepared in Chapter One, with the purified pAb

Section IA: Preparation of Anti-schistosomal Polyclonal Antibodies
against Schistosoma Surface Tegumental Antigens
To prepare the anti- schistosomal pAb, we first prepared the Schistosoma sAg to
immunize the rabbits so that they can produce specific pAb against it.

I.A.1.

Production,

Purification

and

Characterization

of

Tegumental

Schistosoma Antigens “sAg”
I.A.1.1. Production of Schistosoma sAg
Viable Schistosoma haematobium (Egyptian strain) worms were obtained from the
Schistosome Biological Supply Center (SBSC), Theodore Bilharz Research Institute (TBRI),
Giza, Egypt directly after their perfusion from the porto- mesenteric veins of infected golden
hamsters. The collected mature worms were washed three times with sterile PBS (pH 7.4). The
crude excretory/ secretory (E/S) S. haematobium antigens were prepared by incubation of the
parasites overnight in Roswell Park Memorial Institute (RPMI-1640) culture medium,
maintained at pH 7.4 with HEPES (N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid)
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20mM, and supplemented with l-glutamine, 10% Fetal Bovine Serum (FBS) and antibiotics (100
IU/ml penicillin, 100 µg/ml streptomycin and 160μg/ml gentamycin) at 37oC under 5% CO2 in
air.
Following incubation, the medium is removed and centrifuged at14000 rpm for 30 min at
o

4 C. The collected supernatant, containing the excretory-secretory (E/S) crude antigens, is
aliquoted and stored at -20oC till use. 94,95,95–97

I.A.1.2. Purification of Schistosoma sAg
Afterwards, Cysteine proteinases (CP Ag), molecular weight (M.Wt.) of 27-29 kDa, were
purified from the crude extract by a combination of ion exchange chromatography on DEAE
(diethyl amino-ethyl) -Sephadex A-50 column and gel filtration using Sephacryl S-100 HR
column.

I.A.1.2.1. Ion Exchange Chromatography
Ion exchange chromatography is the most popular technique for purification of proteins
based on their net charge. Herein, we purified the prepared crude antigens using DEAE
chromatography. The DEAE group maintains a constant positive charge that is neutralized by
counter ions, usually chloride ions. Other anions are capable of competing for the positive DEAE
group.98 Figure 2.1 is an illustration of the basic principle of ion exchange chromatography.
First, one gram Sephadex A-50 powder was swelled in about 200 ml of 0.5M Tris - HCI
buffer (pH 7.4). Gentle stirring using glass rod during slow addition of the powder to the buffer
was necessary as vigorous stirring might damage the particles. Complete gel swelling took 2
hours at 100˚C in water bath. The high temperature serves to deaerate the medium. After
swelling, the initial supernatant was removed and the swelled gel was washed extensively with
20mM Tris-HCl buffer (PH 6.5), the selected binding buffer. The added 1gm Sephadex A-50
powder was swelled to 22 ml beads. Then, the swelled beads suspension (slurry with 75% settled
beads and 25% buffer) was poured in 30x2.5 cm column in one continuous motion down a glass
rod held against the wall of the column to avoid air bubbles trapping.
Following the settling of beads in the column, the surface was covered with the binding
buffer and the approximate column binding capacity was determined. Since the available
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capacity of DEAE -Sephadex A-50 is 5 gm protein/1g powder so, the column binding capacity
was found to be equivalent to about 227mg protein per 1 ml swelled beads.
On the other hand, the protein sample (Crude Ag) was dialyzed versus the binding buffer
and its protein content was calculated. The outlet tubing of the column was then closed and the
buffer above the beads was removed. The protein content < 10% of column bed capacity (i.e.
mass of beads inside the column) was pipetted to the column. The outlet tubing was opened till
the sample penetration to the beads then closed again for 10 minutes to allow for protein
adsorption to the beads via the ionic interaction between the oppositely charged ionic groups in
the sample proteins and in the functional ligand on the beads. The outlet was then opened and the
beads were washed by 5 bed volumes binding buffer.
The protein was eluted by 20mM Tris-HCl/150 mM NaCl under gravity by collecting
2ml fractions. By using high concentration salt as eluting buffer, the molecules with the weakest
ionic interactions started to elute from the column first then the ones that have a stronger ionic
interaction eluted later. The Absorbance of each fraction was measured at 280 nm and the purity
of the produced protein was assayed by SDS-PAGE (Sodium Dodecyl Sulfate – Polyacrylamide
Gel Electrophoresis). 94,98–100

I.A.1.2.2. Gel Filtration (Size Exclusion) Chromatography
The fraction that showed the highest absorbance reading at 280nm, meaning that it
contains the highest protein content, was further purified using gel filtration chromatography.
This type of chromatography has been used for further separation of proteins, this time, based on
their molecular size. The solid phase matrix (Sephacryl S-100 HR beads) consists of porous
beads that are packed into a column with a mobile liquid phase flowing through the column.
These porous beads act as sieves to filter small molecules which become temporarily trapped
within the pores allowing enough time for large molecules to be pass first from around “be
excluded from” the beads. Thus, protein molecules of different size will elute through the
stationary phase “beads” at different rates and collected as fractions. Figure 2.2 is a
representation of the principle of size exclusion chromatography.
Briefly, the column was prepared by suspending Sephacryl S-100 HR powder in
deionized water. Complete swelling was achieved after 5 hours boiling in water bath. The
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swelled beads (50% settled medium) were poured in 30x2.5 cm column, avoiding air bubbles
trapping as mentioned before, and washed with 3 column volumes mobile phase and left to be
packed for about 24 hours. The outlet of the column was opened for mobile phase penetration in
the gel surface. The sample (4% of the column volume) was layered on the bed surface and left
to penetrate in the beads then the beads were washed by 4 bed volumes of mobile phase.
Fractions (2ml each) were collected under gravity and absorbance at 280 nm of each fraction was
measured. The fraction that showed the highest absorbance value was then analyzed by SDSPAGE under reducing conditions.94,96,98

I.A.1.3. Characterization of Schistosoma sAg
I.A.1.3.1. Protein Content Determination
Concentrations of prepared crude Schistosoma antigen and the purified protein were
determined using Bradford protein quantification technique. This assay is based on the change in
color of the Coomassie dye from blue to reddish brown in direct proportional response to the
various concentrations of bound proteins as this dye has high affinity for protein binding.101–104
Briefly, the dye was diluted with 4 volumes of deionized water and 200µl from the
diluted dye were added to each dilution from the standard and the unknown protein samples in
96-well plate. The absorbance of the color was measured at 595 nm. Serial dilutions of initial
known concentration of bovine serum albumin (BSA) were prepared to reach final
concentrations range from 0 to 1500µg/ml. Consequently, a standard curve was constructed by
plotting the BSA concentration versus absorbance. From the standard curve, the protein content
of unknown samples was calculated. All experiments were carried out as triplicates.

I.A.1.3.2. UV Spectrophotometry
The absorbance of each eluted fraction from both ion exchange and gel filtration columns
was monitored at 280 nm using a UV spectrophotometer. The cut-off absorbance was an optical
density (OD) of 0.05. The fractions containing the specific component with an approximate
molecular weight (M.Wt) of 27-29 kDa (CP Ag) were identified by SDS-PAGE.94,98
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I.A.1.3.3. Molecular Weight Characterization
Purity of 27-29 KDa S. haematobium CP AG was assessed using Sodium Dodecyl
Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) technique. This technique is based on
migration of proteins depending on their charge and size. However, in the presence of sodium
dodecyl sulfate (SDS), all proteins become negatively charged owing to their binding to
negatively charged detergent molecules. When these SDS coated proteins are placed in an
electric field, the separation of the proteins will depend only on their size. 94,99,100
The protein fractions of interest were analyzed by SDS-PAGE under reducing conditions
on a 12 % polyacrylamide gel. For molecular weight estimation, low range pre-stained molecular
weight standards from 18.5 to 106 kDa were diluted in sample buffer 1:20 (v/v). The prepared
samples and low molecular weight standard were applied into the wells of the prepared gel (20
l/well for sample and 10 l for standard) and ran in parallel. After electrophoresis, the resolved
proteins were revealed by staining with Coomassie brilliant blue dye.
The slab gel mold (Figure 2.3) was prepared within two glass plates separated by spacer
bars and stood vertically into a glass cassette. The gel was prepared starting by the separating gel
(12%) (Small pore gel) in the bottom of the slide and the stacking gel 4% (large pore gel) was
poured on top to form the upper gel acrylamide. A plastic comb (1mm) was inserted into the
stacking gel to form the sample wells and left to polymerize for 1 hr.
After polymerization, the comb was removed gently and the slab cassette inserted into the
electrophoresis cell which was filled with the electrode buffer. The current was turned on and the
run was started by 10 mA until the samples entered the stacking gel, and then the current was
raised to 50mA until the samples reached the bottom of the gel. After electrophoresis, the gel
was stained in 0.1% Coomassie blue (w/v) in methanol, acetic acid and water as 4:1:5 (v/v/v)
for 2-4 h , then the excess dye was removed from the gel by destaining solution to visualize the
protein bands. After destaining the gel was stored in 5% acetic acid.

I.A.1.3.4. Assessment of reactivity and specificity of the prepared S.
haematobium CP antigen by indirect ELISA
To assess the reactivity of the purified S. haematobium CP Ag and its specificity to antiS. haematobium immunoglobulins (Antibodies), indirect Enzyme-linked Immuno-Sorbent Assay
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(ELISA) was carried out. Figure 2.4 is a graphical representation of its basic principle. Briefly,
ELISA test involves the passive adsorption of antigen onto the surface of solid phase e.g.
microtiter plate followed by addition of serum containing specific antibodies. Indirect method
involves incubation of the coated antigen with unlabeled antibodies (primary) then enzyme
labeled antibodies specific to the primary one (indirect ELISA). When a suitable substrate is
added, hydrolysis occurs, the degree of which is proportional to the amount of attached enzyme.
The enzyme and the substrate are chosen to produce colored enzyme-substrate breakdown.
94,96,98,105

Wells of polystyrene microtiter 96- flat bottomed wells plates were coated with 1μg/well
of S. haematobium CP Ag in coating buffer (0.05 M carbonate buffer, pH 9.6), then incubated
overnight at 4°C. The plates were washed 3 times with washing buffer 0.1 M PBS pH 7.4, and
then blocked with 200 l/well of 0.1% bovine serum albumin (BSA) in 0.1 M PBS tween-20
(PBS/T) pH 7.2 for 1 hour at 37°C. Following washing the wells 3 times, 100μl/well of diluted
serum samples (1:200) containing primary antibodies diluted in the washing buffer was added
and then incubated for 1hr at 37°C. Three serum samples containing specific antibodies against
Schistosomiasis, Fascioliasis and Ascariasis (To detect for the specificity of tested Schistosoma
Ag towards Anti- Schistosoma Ab) were used.
Then, the plates were washed 3 times with the washing buffer and 100μl/well of the
diluted horse- radish peroxidase-labeled conjugate (labeled secondary antibody) was applied
with incubation for 30min at 37°C. After 3 times washing, 100μl from the freshly prepared
Ortho-phenylenediamine dihydrochloride (OPD) substrate solution in 0.05 M. Phosphate citrate
buffer pH 5 was added to each well. The plates were incubated in the dark at room temperature
for 30 minutes till color appearance. After that, stopping buffer (8 N H2SO4) 50μl/well was
added to stop the over enzyme-substrate reaction. The absorbance was measured at 492 nm using
ELISA reader.
The data were presented as mean ±SD. The means of the different groups were compared
using the analysis of variance ANOVA. The data were considered significant if P values < 0.05.
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I.A.2. Production, Purification and Characterization of Anti-schistosomal
Polyclonal Antibodies “pAb”
I.A.2.1. Production of Anti-schistosomal pAb*
* Experiment

I.A.2.1 was done by Dr. Ibrahim Rabie, Professor of Parasitology, TBRI

In brief, two Newzealand white male rabbits, weighing approximately 3 Kg and about 4
months age, were examined before the immunization with the previously purified Schistosoma
CP Ag for production of anti- Schistosoma polyclonal antibodies (pAb). They were free from
Schistosoma and other parasitic infections. Then, they maintained at the SBSC/TBRI, Giza,
Egypt. They were kept under standard laboratory care (Temperature 25˚C, humidity 45-55%,
filtered drinking water, and 24% protein and 4% fat diet). Animal experiments have been carried
out according to the internationally valid guidelines and ethical conditions. 100,106
For immunization of the rabbits, 1 mg of CP antigen was mixed with an equal volume of
complete Freund's adjuvant (CFA) and injected intramuscularly into each rabbit. Booster doses
(0.5 mg mixed with an equal volume of incomplete Freund's adjuvant (IFA)) were administered
at week 2, 3 and 4 after the initial dose. Sera were collected 4 days post last injection from ear
vein. 100,107
Blood samples were withdrawn from the rabbit's ear before the first intramuscular
injection and examined by indirect ELISA for cross reaction with other parasite (to make sure
that the rabbit was clean from any infection with other parasites) and after injection of each
immunizing dose (boosting) to detect the titer of specific anti-S. haematobium antibodies
produced. When the titer was high approximately the fourth day post last injection), the animal
was scarified and blood samples were collected and antisera were further purified as explained
below. 106,107

I.A.2.2. Purification of Anti-schistosomal pAb
The collected rabbit serum containing the anti- Schistosoma pAb were purified on three
successive steps. First, ammonium sulphate precipitation method was used followed by Caprylic
acid purification technique. Finally, the partially purified protein is separated on DEAE anion
exchange chromatographic column.
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I.A.2.2.1. Ammonium Sulfate Precipitation
The principle of this method is based on the fact that proteins in solutions form hydrogen
bonds with water through their exposed polar and ionic groups. When high concentration of
highly charged ions such as ammonium or sulfate is added, these groups compete with the
proteins for binding to water. This removes the water molecules from the proteins and decreases
its solubility, resulting in their precipitation. 98
Briefly, saturated ammonium sulfate solution was prepared by dissolving 100 g of
ammonium sulfate in 100 ml deionized water, at 50oC and kept overnight at room temperature.
After complete dissolving, the supernatant was separated and the pH was adjusted to 7.4 using
concentrated ammonia. On the other hand, Anti–CP polyclonal antibodies were centrifuged at
11000rpm in cooling centrifuge at 4oC for 20 minutes to remove any debris.
The saturated solution was then added drop wise to anti–CP polyclonal antibodies to
reach 50 % saturation, with continuous stirring. Afterwards, centrifugation at the same
conditions was done. Supernatant was discarded. The precipitate was dissolved in a suitable
amount of 0.01 M PBS, pH 7.4. The ammonium sulfate was removed by dialysis against 0.01 M
PBS pH 7.4 for 72 days at 4oC.

I.A.2.2.2. Caprylic Acid Purification Method
The principle of this method is based on the fact that the addition of short-chain fatty
acids such as caprylic acid in mildly-acidic conditions to the serum. will precipitate most serum
proteins with the exception of immunoglobulin G (IgG), which is the protein developed in
response to Rabbit immunization with the Schistosoma CP antigen. 98
Briefly, the Anti–CP polyclonal antibodies, partially purified by ammonium sulfate
precipitation were diluted with 2 volumes of 60 mM sodium acetate buffer pH 4.8. Then, 7%
caprylic acid was added drop wise with slow magnetic stirring for 30 minutes at 4 oC. The
mixture was then centrifuged at 11000rpm for 30 minutes at 4oC; serum proteins except IgG
were separated and removed in the precipitate while the supernatant, containing nearly pure

IgG, was further purified.
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I.A.2.2.3. Ion Exchange Chromatography
The same technique that was demonstrated under subsection (I.A.1.2.1) was repeated.
However, the purified anti- CP IgG sample was applied to the column. Upon fractionation, the
absorbance of each collected fraction was measured at 280 nm via UV Spectrophotometry.
The fraction exhibiting the highest absorbance (The purified anti- Schistosoma pAb) was
further characterized for its protein content (Bradford Protein Quantification Assay), purity
and molecular size (SDS-PAGE), and finally, its specificity against S. haematobium CP Ag
(Indirect ELISA).

Section IB: Preparation and Characterization of PLGA Nanoparticles Surface
– Modified With Purified Anti- Schistosoma Polyclonal Antibodies
The aim of the study was to functionalize the surface of the optimized PZQ- loaded
PLGA NPs formula (VII4) with the purified anti- Schistosoma pAb in order to achieve a specific
drug carrier system against schistosome surface antigens. Presumably, when such a drug delivery
system (DDS) is administered systemically, it will help for active targeting of the drug towards
Schistosoma parasites in host blood circulation. Table 2.1 summarizes the properties of the
chosen optimum formula and its blank.

I.B.1. Preparation of Polyclonal Antibody- Coated PLGA NPs “Immuno-NPs”
Two methods for coating the surface of PLGA NPs were studied. The first one is the noncovalent physical adsorption of the pAb to the NPs’ surface and the second method is the
covalent conjugation through carbodiimide chemistry. The method for the preparation of
immuno-NPs was optimized on the basis of pAb- coupling efficiency, the amount of adsorbed or
conjugated pAb to PLGA NPs (%w/w) and the reactivity of the coupled pAb against
Schistosoma CP Ag. The prepared immuno-NPs were also characterized for their size, size
distribution, charge, drug encapsulation and drug loading in order to assess the effect of coating
method on the properties of the optimized PLGA NPs.

I.B.1.1. Physical (Non- Covalent) Adsorption Method
The prepared PLGA NPs (0.5 mg/ml) were first dispersed in PBS, pH 5.5, by sonication
for 20 seconds. Specified volumes of the solution containing the purified pAb (2 mg/ml) were
then added to the NPs’ suspensions and the volumes were adjusted using PBS, pH 5.5 to reach
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the final specified ratios mentioned in Table 2.2 (Experiment I-2: Studying the effect of the
amount of added pAb “pAb:PLGA (%w/w)” on adsorption efficiency) . The mixtures were
mixed very well by vortexing at room temperature then, left for either 12 hours or 24 hours
(Experiment I-1: Studying the effect of incubation time on adsorption efficiency, Table 2.2) at
4oC to allow for pAb adsorption on the surface of PLGA NPs. After that the suspension was
centrifuged for 15 minutes at 11000rpm in a cooling centrifuge to separate immuno-NPs from
free pAb. The precipitate was washed twice for 10 minutes with PBS, pH 7.4 then, re-suspended
in the same buffer for further use. The supernatant from both purification and washing
centrifugation steps was collected for quantification of the free unattached pAb by Bradford
protein quantification method. The control was run the same way as the sample but PBS was
used instead of pAb solution as illustrated in Table 2.2.108,109

I.B.1.2. Chemical (Covalent) Conjugation Method
For covalent attachment of anti- CP pAb onto the PLGA NPs surface, EDC/NHS
carbodiimide chemistry was employed.110–113 Briefly, PZQ- loaded PLGA NPs (0.5mg/ml) were
dispersed in PBS, pH 7.4. Then, carboxylic groups (-COOH) were activated prior to their
incubation with antibody by addition of the water-soluble 1-ethyl- 3-(3-dimethylaminopropyl)
carbodiimide (EDC), 2mM and 5mM N- hydroxysuccinamide (NHS) in PBS, pH 5.5 to the
suspension. The sample was stirred at RT 1 h on a rotating wheel. Then, the sample was
centrifuged at 11000 rpm, 4oC for 15 min to remove unreacted EDC and NHS. The process was
repeated twice and the precipitated particles were washed each time with PBS, pH 7.4.
Afterwards, the pellet obtained after washing was suspended in PBS, pH 7.4 and a
buffered solution containing the determined amount of pAb was added (Table 2.3, Experiment
II-1: Studying the effect of the amount of added pAb “pAb:PLGA (%w/w)” on conjugation
efficiency). The mixture was rotated for 1hr at RT before overnight incubation at 4oC. Then, the
formulated immuno-NPs were purified and collected by centrifugation three times at 11000 rpm,
4oC for 20 min to remove any excess unconjugated pAb. The final precipitated pellet was
suspended in PBS pH 7.4 for further experiment. The supernatant was collected during the
washing steps to measure the amount of unconjugated pAb spectrophotometrically at 595 nm
using ELISA plate reader. Again, the control was run the same way as the sample but PBS was
used instead of pAb solution as illustrated in Table 2.3.
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I.B.1.3. Statistical Analysis
All experiments were carried out three times, independently. Results are expressed as
mean ± standard deviation (SD). Significant statistical differences between groups were
examined by applying Student's t-test for two groups’ comparison and one-way analysis of
variance (ANOVA) for three or more groups. The statistical significance level (P-value) was set
at ≤0.05. Statistical analysis was done to all data obtained for all NPs formulae. All tests were
calculated using the software GraphPad Prism Software Version 6, San Diego, CA.

I.B.2. Characterization of Polyclonal Antibody- Coated PLGA NPs
All prepared formulations of both pAb- adsorbed and pAb-conjugated PZQ-loaded
PLGA NPs were characterized on basis of their size, size distribution, charge and drug
encapsulation (Refer to methodology section in Chapter One) to assess the effect of coating
methods on the optimized properties of PLGA NPs. In addition, the amount of attached pAb to
the surface of PLGA NPs was quantified and the adsorption and conjugation efficiencies were
calculated. Accordingly, the optimum immuno- NPs formulae were selected and the reactivity
of pAb, after being attached to NPs, against S. haematobium CP Ag was assessed using dot blot
immuno- assay.

I.B.2.1. Quantification of pAb on Surface of PLGA NPs
The amount of attached pAb on the surface of PLGA NPs was determined using Bradford
protein quantification assay (Refer to subsection I.A.1.3.1., Chapter Two). An indirect method
was used where the pAb concentration was quantified in the supernatant collected during the
purification and washing steps of the prepared immuno-NPs. Then, the actual attached pAb
concentration was calculated, based on the constructed BSA standard curve, by subtracting the
measured concentration from the initial used one. All analysis was performed in triplicate.
64,113,114

I.B.2.2. Bioactivity Assay
This experiment was done to test for the reactivity of pAb against sAg after being
adsorbed or conjugated to the surface of NPs; as it has been known that attaching the bioactive
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molecules, particularly via chemical conjugation, often reduces their activities. 75 The bioactivity
of pAb- conjugated PLGA NPs was assessed qualitatively using modified dot blot immunoassay and compared to that of free pAb (Positive control). 115–117
An indirect type immuno-assay (Figure 2.5) modified approach was successfully
developed for pAb-PLGA NPs bioactivity evaluation. Concisely, an identified amount of S.
haematobium purified CP Ag (1µg), diluted in 1X Tris- buffer saline (TBS, pH 7.4), are spotted
on to wet nitrocellulose membrane and left to dry for 1hr at RT. Upon that active sites on the
membrane were blocked using 3%w/v skimmed milk powder for 1 h at 37oC with gentle
agitation followed by washing thrice in TBS – 0.2% Tween 20 (TBS-T), pH 7.4.
After washing, immuno-NPs surface coated with purified anti-CP pAb via carbodiimide
conjugation reaction, Formula C5 in concentration equivalent to 1µg pAb in TBS-T buffuer and
its Blank (Formula C1) were pipetted over previously spotted sAg on the membrane. Purified
CP antibody (Primary antibody) alone was applied to serve as positive control for the
experiment. On the other hand, negative control was run in parallel by adding buffer free of
antibody or immuno-NPs. Incubation at 4oC was followed overnight to allow enough time for the
formation of sAg-pAb complexes. Unconjugated primary antibody was washed away with TBS,
pH 7.4 thrice.
The formed complexes were detected through reaction with enzyme- linked secondary
antibody “Horse Raddish Peroxidase (HRP) conjugated anti-rabbit secondary antibody at
concentration (1/10000 dilution)” and incubated for 1 h at 37oC. In turn, unbound secondary
antibody as well was removed by washing. Washed membranes were then incubated with soluble
uncolored TMB liquid substrate diluted in TBS and left to develop the color for 10 minutes. The
enzyme-substrate conjugate was converted to an insoluble purple product by the enzyme. The
intensity of the developed color was used as an indication of activity of antibody present in the
sample. Finally, the membranes were dried and scanned. Each control and sample was carried
out in triplicates.
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Section II: Results and Discussion
Section IIA: Preparation of Anti-schistosomal Polyclonal Antibodies against
Schistosoma Tegumental Antigens
In this study, S. haematobium parasites were collected from the porto- mesenteric veins
of infected hamsters and the E/S crude antigen was extracted from the worms as explained
earlier. The crude sAg was then purified on two steps using ion exchange and size exclusion
column chromatography methods. The purified CP antigen was further characterized to evaluate
its protein content, molecular size, bioactivity and specificity against anti- CP antibody.
Figure 2.6 shows the OD280 profile of the antigen fractions obtained following
purification of E/S products of adult S. haematobium worm by DEAE Sephadex A-50 ion
exchange chromatography using UV spectrophotmetry. The eluted antigen is represented by a
single peak with maximum OD value equal to 2.64 at fraction number 11 representing the eluted
antigen (the fraction with the highest protein content). The eluted proteins from the DEAESephadex A50- ion exchange column chromatography were analyzed by 12.5% SDS-PAGE
under reducing conditions (Figure 2.9), showing several bands of different molecular sizes
representing the cysteine proteinase antigen along with other proteins. The band showed at 27-29
kDa was the one of interest representing the CP antigen.
The partially purified Cysteine proteinase antigen obtained following purification by
DEAE Sephadex A-50 ion exchange chromatography (Fraction number 11) was further purified
by Sephacryl S-100 HR gel filtration column chromatography and one peak was obtained
representing the column elution volume fractions which contain the highest protein content with
OD value 1.91 at fraction number 7 (Figure 2.7).

The eluted proteins from the gel filtration

column chromatography, analyzed by 12.5% SDS-PAGE under reducing condition showed
only one band at 27.5 kDa which was cysteine proteinase antigen (Figure 2.9).
For protein content determination, Bradford protein assay was performed. First, BSA
(Bovine serum albumin) standard curve was established. Serial dilutions from BSA stock
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solution of known concentration were prepared (Table 2.4). The assay was conducted as
explained under the methodology section and the absorbance was measured for the different
dilutions at 595nm. Concentrations were plotted versus absorbance and a calibration curve was
generated, as shown in Figure 2.8. Polynomial equation (R2 = 0.999) was obtained and used for
calculations of protein concentration. It is worth mentioning that the polynomial equation
resulted in more accurate calculations of protein concentration, even though several trials were
done for linearization of Bradford protein assay.

101,102,104,114

Two ranges of serially diluted BSA

concentrations were used in order to achieve more accurate determination of protein content at
very low concentrations (0-25µg/ml), as illustrated it Table 2.4b and Figure 2.8b.
Then, the total protein content of the E/S crude antigen products of S. haematobiumwas
measured. It contained 2.7±0.045 mg/ml of total protein. While, after purification, the final
protein content of purified S. haematobium CP antigen was 1.85±0.071 mg/ml.
Furthermore, to confirm the purity of the 27-29 kDa separated fraction (Purified CP sAg),
the eluted proteins gained from the different purification steps were analyzed by 12% SDSPAGE under reducing conditions. Figure 2.9 shows the gel profile of adult S. haematobium
worm antigens (The crude E/S sAg before purification, the partially purified CP sAg after ion
exchange column chromatography and the purified CP sAg). Low molecular weight of standarad
proteins was run in parallel showing different bands ranged from 18.5 -106 kDa to help estimate
the molecular size of the eluted proteins. Stained gels showed that the crude antigen productss
was separated in multiple bands of M.Wt. ranging from 12-117 kDa with major bands of 105, 79,
66, 58, 45, 34, 29, 27 and 14 kDa and minor bands of 100, 38, 36, 32, 25 and 12 kDa. On the
other hand, SDS-PAGE profile of the purified fraction showed a single homogenous band of 2729 kDa. The 27-29 kDa molecules have been reported earlier as the S. haematobium CP enzyme
(ShCP3) based on its similarities to a 28 kDa CP from S. mansoni.

106

Based on this, we

suggested that our purified sAg might be the S. haematobium CP reported earlier.
Reactivity and antigenicity of the purified target CP antigen was evaluated by indirect
ELISA technique. Herein, serum samples from S. haematobium infected rabbits gave a strong
reaction against S. haematobium CP products with absorbance reading equal to 1.41 ± 0.09.
While, no cross reactivity was recorded with sera of rabbits infected with other parasites e.g.,
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fascioliasis, and ascariasis (Table 2.5) as the absorbance reading for S. haematobium was
significantly higher than the ones obtained from the sera containing pAb against other parasite
infections. This confirms the specifity of our CP sAg against S. haematobium pAb.
Consequently, male New Zealand white rabbits were immunized with the purified S.
haematobium CP antigen and the reactivity of the produced anti- S. haematobium CP pAb
against the purified tegumental antigen along with other parasites (Fasciola, Ancylostoma and
Ascaris) were determined by indirect ELISA. The immunoglobulin G (IgG) fraction of rabbit
anti- S. haematobium pAb was purified from the total produced immunoglobulins (pAb) titre
using ammonium sulphate precipitation method followed by 7% caprylic acid treatment
and finally by using ion exchange chromatography method (DEAE Sephadex A-50).
Test blood samples were withdrawn from New Zealand white rabbit before the injection
of each immunizing dose. They were tested for the presence of specific anti-S. haematobium
antibodies by indirect ELISA. An increasing antibody level started 1 week after the first booster
dose. Three days after the 2nd booster dose immune sera gave a high titre against S. haematobium
CP with OD of 2.97 at 1/250 dilution (Figure 2.10)
Since proteins in solutions have been known to form hydrogen bonds with water which,
in turn, increase their solubility, ammonium sulfate precipitation methods was used to remove
these water molecules via competing with them and precipitating the protein molecules after
forming more favorable hydrogen bonds.98 The IgG (The target pAb) was further purified from
serum proteins by caprylic acid treatment. Protein content was estimated after each purification
step using Bradford assay. The purity of the produced IgG was identified by 12% SDS-PAGE
(1mm) under reducing conditions.
Figure 2.11 shows the OD280 profile of the IgG fractions obtained following purification
by DEAE Sephadex A-50 ion exchange column chromatography by UV spectrophotometry.
The eluted IgG is represented by a single peak with maximum OD value 2.88 at fraction number
9.
The total protein content of crude rabbit serum containing anti- S. haematobium CP
pAb was found to be 3.1±0.45mg/ml and 2.63±0.89mg/ml after 50% ammonium sulfate
precipitation method, while following 7% caprylic acid precipitation method the content
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decreased to 2.21±0.19mg/ml. Finally, the protein content of highly purified anti- S.
haematobium CP IgG pAb subjected to ion exchange chromatography method was 1.99±0.28
mg/ml.
The purity of IgG pAb after each purification step was assayed by 12% SDS-PAGE
under reducing conditions. Analysis of 50% ammonium sulfate- precipitated proteins showed
several bands. While the purified IgG pAb after 7% caprylic acid was represented by only two
characteristic bands, light (L-) and heavy (H-) chain bands at 31 and 53 kDa, respectively
(Figure 2.12). General structure of antibody was illustrated in Figure 2.13.63
Reactivity and specificity of anti- S. haematobium CP IgG pAb against S. haematobium
CP antigen and other parasite antigens (Fasciola and Ascaris) were assessed by indirect ELISA.
The produced anti- S. haematobium CP IgG pAb gave strong reactivity to S. haematobium CP
sAg. The mean absorbance readings at 492 nm for S.haematobium CP (2.37± 0.12) were
significantly higher than that of Fasciolia and Ascaris infected sera (0.21±011 and 0.27±0.08 for,
respectively) as shown in Table 2.6.

Section IIB: Preparation and Characterization of PLGA Nanoparticles Surface
– Modified With Polyclonal Antibodies
The prime objective of this study was to prepare and evaluate pAb- coated PLGA NPs
capable of targeting Schistosoma parasites and delivering PZQ near its site of action. As a result
of drug targeting, the efficacy of therapy and reduction of side effects associated with the drug
can improve.
To achieve targeting of schistosomes, we used polyclonal antibodies (pAb), developed
against cysteine proteinases surface antigens (CP sAg) of Schistosoma worms specifically S.
haematobium Egyptian strain, for surface coating of the optimized PZQ- loaded PLGA NPs.
Polyclonal antibodies (pAb) were applied instead of monoclonal antibodies (mAb) as they are
capable of recognizing several epitopes on the target protein rather than recognizing only single
epitope as in case of mAb. Although, mAb are more specific than pAb, sometimes they are not
able to precipitate the antigen because the epitope might need to be exposed on the surface of the
antigen to be recognized by the antibody. Since some of the epitope might be hidden and it's a
single epitope that is recognized by the mAb, the probability of the antibody to recognize the
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epitope is lower compared with that of pAb which recognizes several epitopes on the target
protein.118–120
Two different strategies were applied to attach the amine groups of pAb to the carboxyl
groups on PLGA NPs. The first method was depending on the physical non- covalent adsorption;
while the second procedure involved the chemical covalent modification of NPs using EDC/
NHS carbodiimide coupling reaction.
In the first method, NPs were incubated with pAb to allow non-specific adsorption onto
their surface, as reported by Kockbek et al.108 It has been suggested that the adsorption process
results generally from the hydrophobic interactions between the non- polar hydrophobic groups
of the antibody molecule and the hydrophobic PLGA polymer.63,109,121 However, in our case, as
we prepared the PZQ- loaded PLGA NPs using uncapped acid-terminated PLGA rather than the
more commonly used hydrophobic ester-terminated PLGA, several other mechanisms might
contribute in the adsorption process as well.
First, hydrophobic interactions might contribute in the adsorption attraction though with a
lesser extent in case of acid – terminated PLGA as the exposed non- polar areas on the polymer
would be minimized. Wan der Waal forces and hydrogen bonds might be contributors in
adsorption as well. Since the adsorption process was allowed to take place at pH 5.5, the slightly
acidic pH helps the ionization of surface carboxyl groups. Consequently, the non- covalent
adsorption of pAb on the surface of PLGA NPs might be due to electrostatic interactions
between the oppositely charged carboxyl and amino groups; however, the carboxylic groups
were not being fully activated on the surface of NPs. Even though these interactions are known
to be strong enough and even might be stronger than covalent bonds, they could be easily broken
with possible changes in the reaction environment like change in pH or addition of
water.63,81,122,123 This might make the adsorption process reversible. Several authors emphasized
the importance of competitive displacement of pAb that can take place in the presence of serum
components “Plasma proteins”.

108

The process of adsorption of peptides to PLGA surface is

most favorable when the peptide is uncharged, thus less soluble, and exerts more hydrophobic
character that interacts with the hydrophobic surface of polymer.108
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While in the second method, we assessed EDC/NHS chemistry for covalent coupling
of PLGA particle surface carboxyl groups and pAb ligand amine groups via amidation reaction.
EDC is frequently used for coupling reactions with bioactive molecules; it is a zero length cross
linking agent forms stable intermediates with carboxyl groups in the presence of NHS which
react with nucleophiles, such as primary amines to form amide bonds.110,123–127 Furthermore, in
the absence of primary amines, the activated intermediates hydrolyze back to the free carboxyl
form. Aqueous solubility of EDC and NHS limits exposure of PLGA particles to extreme solvent
conditions during activation. Figure 2.18 is a schematic illustration of the EDC/ NHS
carbodiimide crosslinking reaction.
For this reaction, PLGA carboxylic functional groups were first activated through
exposure with EDC /NHS in a medium consisting of PBS buffer, pH=5.5; as the carboxyl group
should ideally remain mostly in its deprotonated form (RCOO-) so as to act as a nucleophile in
the reaction. The activated NPs were then purified and then exposed to pAb solution in PBS, pH
=7.4. The conjugated COOH groups were made to react with –NH3+groups present on the pAb
molecules to make immuno-NPs. They were then isolated by centrifugation steps and the
supernatant was collected for indirect measurement of attached pAb on surface of PLGA NPs. 84
After purification of immuno-NPs, the amount of coupled pAb on PLGA NPs was
quantified using Bradford assay. A standard curve constructed using a known BSA
concentration range was used for comparison in each experiment as mentioned earlier (Table 2.4
and Figure 2.8). The bioactivity of the pAb on the surface of NPs was assessed by dot blot
immuno-assay. In addition, the physical characteristics of PZQ- loaded PLGA NPs were reevaluated to assess the effect of adsorption and conjugation methods after attachment of pAb on
their surfaces.
Table 2.7 summarizes the evaluation results of pAb- adsorbed PLGA NPs. The data
was expressed as mean ± SD of triplicate experiments. Two parameters were studied: the
incubation time allowed for adsorption to take place (Expt.: I-1) and the initial amount
added of pAb, µg (Expt.: I-2). The amount of PLGA NPs was fixed for all formulae (500 µg).
As shown in Table 2.7, four ratios of pAb: PLGA (%w/w) were used in Expt. I-2, namely: 1:1,
1:25, 1:50 and 1:100. The results presented in Table 2.7 and Figure 2.14 demonstrate no
significant difference in the adsorption efficiency of formulae A2 (12 hours incubation) and A4
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(24 hours incubation); though both of them had significantly higher adsorption efficiency if
compared with their controls (A1 and A3 respectively), p-value<0.0001. The adsorption
efficiency of pAb to NPs was 37.4± 2.99 and 38.1± 2.05 for A2 and A4 respectively with
approximately 0.374μg and 0.381 of pAb was adsorbed per mg of NPs.
Regarding the effect of adsorption time on the physical properties of the optimized PZQloaded PLGA NPs (Figure 2.15), it was noticed that although there was a slight increase in the
size and PDI of pAb- adsorbed PLGA NPs, the difference was non- significant (Figure 2.15a).
On the contrary, the increase in zetapotentail of pAb- adsorbed PLGA NPs was statistically
significant than the control (Uncoated PLGA NPs) (Figure 2.15b). The charge of A2 was 11.32±1.99mV which is significantly higher than that of A1 (-22.01±0.72mV), p-value<0.001.
Similarly, zetapotential of A4 was -10.19±2.81mV which is significantly higher than that of A3
(-21.3±0.91mV), p-value<0.001. Yet, there was no difference between A2 and A4. The increase
in zetapotential values might be attributed to the attachment of pAb onto the surface of PLGA
NPs, masking the free carboxyl groups of PLGA as a result of which the negativity of NPs
decreases though not to a great extent that might affect the physical stability of NPs and lead to
aggregation of immuno-NPs.64
Referring to the results showing the effect of time allowed for adsorption on PZQ
encapsulation efficiency, it was evident that, although, there was no significant effect on it in
both cases of incubation for 12 or 24 hours (A2 and A4) when compared with the controls (A1
and A3). Allowing 24 hours for adsorption lowered the EE% by about more 4% than when
incubating the NPs with pAb for 12 hours only ( 87.02±3.39% instead of

91.89±4.19%,

respectively) (Figure 2.15c). Based on the above obtained data, 12 hours adsorption time was
selected and fixed throughout the next experiment (I-2).
Adsorption of various initial pAb amounts had major effect on the amount adsorbed on
the surface of PLGA NPs expressed as % weight of adsorbed pAb per mg of PLGA NPs (Figure
2.14). Ratio of 1:1 (A9) was statistically significant than the other studied ratios (1:25, 1:50 and
1:100 representing formulations A8, A7 and A6 respectively) in terms of the amount of adsorbed
pAb per mg PLGA, p-value<0.0001. A9 showed also significant higher adsorption efficiency
than both A6 and A7 (64.2±2.87% compared to only 37.4± 5.01 and 36.8±1.99% respectively, p46

value<0.0001) but, no significant difference than A8 in terms of adsorption efficiency (59.5±3.09
%). Accordingly, ratio of 1:1 was chosen as the optimum level along with 12 hours for
adsorption time as mentioned earlier, formula number A9.
While, Table 2.8 presents the characterization data of pAb- conjugated PLGA NPs via
EDC/ NHS covalent conjugation method. Results were represented as mean ± SD of three
independent experiments. The effect of initially added pAb to PLGA NPs ratio on the
conjugation efficiency was studied (Expt. II-1). The results illustrated in Table 2.8 and Figure
2.16 revealed that formula C5 prepared using 500µg pAb (1:1 pAb:PLGA, %w/w) showed
significantly higher amount of conjugated pAb per mg of PLGA NPs than the other three
evaluated ratios (1:25 “C4”, 1:50 “C3” and 1:100 “C2”), p-value< 0.0001(The amount of pAb
covalently bound to NPs surface was shown to be approximately 89.31 µg pAb per 1 mg of
PLGA NPs.). It also showed higher significant conjugation efficiency than C2 and C3, but not
statistically higher than C4.
By re-evaluating the physical characteristics of the PZQ- loaded PLGA NPs after pAb
conjugation (Figure 2.17), it was found that there was negligible effect on PZQ encapsulation
efficiency. This finding was in agreement with that of several previous studies.
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In contrast,

there was significant increase (p- value <0.05) in the zetapotential of pAb-conjugated PLGA
NPs, formulae C4 and C5, in comparison with plain NPs (Control, C1) as represented in Figure
2.17b (-12.2 ±3.1 mV and -11.98±2.27mv compared with -21.97±1.89mV, respectively);
whereas there was non- statistically significant increase in charge of both C2 and C3 (-16.7±1.45
and -18.1±2.72mV). This decrease in negative zeta potential is probably due to the involvement
of carboxylic functional groups on PLGA NPs in amide bond formation with amino acids in pAb
primary structure. This, in turn, support increased association of pAb in the presence of
EDC/NHS.84
Referring to NPs size and size distribution results, it was clear that conjugation of pAb
on surface of PLGA NPs slightly increased the size and PDI at ratios 1:1 and 1:25 of pAb: PLGA
(%/w/w), formulae C5 and C4 respectively (222.78±4.56nm and 230.4±4.19nm instead of 202.1
±3.15nm for plain NPs, C1). Interestingly, at ratios 1:50 and 1:100 (Formulae C3 and C2,
respectively), there was a huge significant increase in particles’ average diameter
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(616.98±10.1nm and 637.2±8.12) and PDI (0.398±0.2 and 0.42±0.092). This could be attributed
to the presence of active sites on PLGA NPs that interact with the ones on other particles leading
to bridging and cross-linking of two or more particles together and in turn the heterogeneous
distribution of the NPs population.84
On the contrary, at higher initial amounts of pAb added for conjugation, saturation of
these activated sites on PLGA NPs was achieved. From these results, it was clear that a ratio of
1:1 (pAb:PLGA) appeared to produce the best conjugation efficiency in terms of the conjugated
pAb amount and bioactivity. 64
The selected optimized pAb- adsorbed PLGA NPs, Formula A9 and pAb- conjugated
PLGA NPs, Formula C5 (Table 2.9 and Figure 2.19) were evaluated for their targetability. The
reactivity of the attached anti- CP pAb was assessed while on the surface of PLGA NPs against
Schistosoma CP sAg using dot blot immunoassay in an indirect manner. 106 In this approach, a
known amount of pAb and pAb-PLGA NPs were applied over CP sAg which in turn was spotted
and dried onto a NC membrane and then reacted with a peroxidase coupled secondary antibody.
A soluble, uncolored substrate was then added which could be converted to an insoluble
purple/violet product by the enzyme. Violet color development depended on the amount of
enzyme present. Three negative controls were run in parallel (No pAb and two formulae
representing uncoated PLGA NPs, Formula A5 and Formula C1). Positive control was also
tested using free pAb. Obtained results were represented in Figure 2.20.
The intensity of the developed color was directly proportional to the strength of the pAbsAg interaction. As a result, scores was given to describe the intensity of the color and in turn the
bioactivity of pAb ranges from 0 to 3. Score of zero means there was no interaction at all; while
scores 1, 2 and 3 (light, moderate and heavy color intensity) indicates weak, medium and strong
bioactivity respectively. From Figure 2.20, it was clear that the pAb- conjugated NPs reacted
strongly with the spotted CP sAg on the membrane. The reaction seems to be stronger than that
of the pAb-adsorbed NPs which in turn is weaker than that of free pAb. This might be due to the
reversibility of adsorption process as mentioned earlier leading to loss of part of adsorbed
antibody during the washing steps of the dot blot immunoassay.
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Other PLGA surface functionalization studies reported the loss of bioactivity of pAb after
being conjugated to NPs chemically.

108,128,129

This might be due to the involvement of the

reactive regions of the pAb in the formation of the amide bond during the conjugation reaction or
the conjugation of excess amount of ligand causing steric hindrance of the reactivity towards
sAg.128,129
It is worth mentioning that several different attempts were made to measure the
biological activity of the immuno-NPs in a quantitative manner. Accordingly, standards of
purified anti-CP antibody were prepared at serially diluted known concentrations, spotted onto
membrane, and treated in an identical manner to that described above. When spot intensity was
plotted against antibody concentration the curves were not linear and a standard curve, against
which purple color development in samples could be compared, could not be well established
(Data not shown). The assay needed to be further optimized and standardized in terms of
quantitative estimation of the developed color intensity.
To conclude, in an attempt to formulate immuno-NPs for targeted delivery, pAb coated
PZQ- loaded PLGA NPs were developed for targeting Schistosoma parasites. On the basis of
size, homogeneity of size distribution, zetapotential, encapsulation efficiency, ligand coupling
efficiency, amount of attached pAb on the surface of PLGA NPs and the bioactivity of pAb upon
attachment to the NPs, the surface functionalization method of the PLGA NPs was hence
selected and used for further experimentation. Out of both prepared immuno-NPs, pAbconjugated immuno-NPs, Formula C5, was found to be optimum and can be used further for in
vitro schistosomicidal studies.70

49

Conclusion
Despite the enormous efforts for control and elimination, schistosomiasis is still an
important worldwide health problem in more than 76 countries including Egypt. In fact, this
neglected tropical disease exerts substantial medical, economic, and psychosocial impacts on the
populations in endemic regions.

11

Unfortunately, schistosomiasis is not assumed to be

eliminated in the near future; so, awareness of the various aspects of the disease is still needed in
endemic countries.
It is likely that PZQ may remain the anti-schistosomal drug of choice for many years in
the future.

17

However, due to its short plasma half-life and rapid metabolism by liver enzymes,

the therapeutic potential becomes significantly reduced.18 Thus, a variety of approaches have
been proposed to overcome the limitations faced during its administration. Nanomedicine
provides a promising approach for specific drug delivery to avoid the high dose toxicity and the
development of resistance against the drug due to massive administration of large doses.
Biocompatible and biodegradable polyester polymers such as PLGA can be formulated
into NPs with control over their physical properties.

81

PZQ- loaded PLGA NPs were prepared

by single (o/w) emulsion solvent evaporation method and physicochemical characterization of
drug loaded NPs system was performed. Small sized NPs (~200nm) with negative zetapotential
were obtained that resulted in development of physically stable nano-carriers which could escape
the reticuloendothelial system preventing their uptake by macrophages. 84
Besides, good morphology in terms of the NPs surface, characterization of the
physiochemical properties of the encapsulated drug within the NPs was also conducted. DSC and
FTIR analysis helped in determining the chemical integrity of PZQ and its interaction with the
polymer. Both confirmed that the drug retained its properties even when encapsulated inside
NPs. Moreover, a sustained release of PZQ illustrated by the in vitro drug-release study indicated
proper diffusion of drug from the polymeric PLGA NPs for its effective anti- schistosomal
action.
Specific drug delivery can be achieved by targeting that may be either active or passive.
130

In active targeting, different targeting moieties can be used, which are conjugated on to the
50

surface of NPs. Herein, PLGA NPs surface modified with anti-CP pAb were developed and fully
characterized. Non- covalent adsorption and direct covalent coupling of antibodies to surface of
PLGA NPs were compared as two different surface functionalization methods to achieve active –
targeted and specific drug carrier systems. The pAb- chemically conjugated to PLGA NPs, in
which the amine groups of the anti-CP pAb were made to covalently couple with the activated
carboxylic groups present at the surface of PLGA NPs in the presence of EDC/NHS by forming
an amide linkage, were selected for further in vitro schistosomicidal studies.
The newly developed NPs had an acceptable size and zetapotential and showed
promising results in both adult and juvenile S. haematobium cultures (Data not shown). It has
been shown that the anti- schistosomal activity of PZQ increased after conjugating a targeting
ligand, anti-CP pAb, onto the PLGA NPs surface. Specific targeting and higher uptake of the
immuno-NPs by schistosome parasites resulted in enhanced anti- schistosomal effect of the
encapsulated drug, PZQ.
It seemed that surface modification of PLGA NPs with anti- CP may represent a
promising approach for active targeting of schistosomiasis. We even can postulate that a similar
approach may be used to develop drug loaded immuno-NPs for treatment of different human
diseases mainly in the field of neglected parasitic diseases in near future.48
Such a nano- carrier system for PZQ delivery is multifunctional, which have several
benefits. It reduces the side effects of the formulated drug, promotes synergistic therapeutic
effects between the bioactive ligand (anti- schistosome pAb) and entrapped drug, and achieves
targeted delivery of therapeutic drug. Thus, the developed drug delivery system (DDS) was able
to provide an efficient and targeted delivery of PZQ for schistosomiasis treatment.
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Appendixes
Appendix I: Materials*
*

All used Solvents were analytical grade and were used without further purification. All aqueous solutions were
prepared with twice distilled and degassed water, deionized and filtered with Millipore Elix 3 System.

 DL-Lactide/Glycolide copolymer (PLGA), Lactide/Glycolide ratio 75:25 with
intrinsic viscosity 0.2 dl/g, PURASORB PDLG 7502A, Purac Biomaterials,
Netherlands
 DL-Lactide/Glycolide copolymer (PLGA), Lactide/Glycolide ratio 50:50 with
intrinsic viscosity 0.4 dl/g, PURASORB PDLG 5004A, Purac Biomaterials,
Netherlands
 Dichloro methane (DCM), analytical grade, Sigma- Aldrich, USA
 Ethyl Acetate (EA), puriss, Sigma-Aldrich Co., USA
 Acetone, Sigma-Aldrich Co., USA
 Poly vinyl alcohol (PVA), 87-90% hydrolyzed, M W 30,000-70,000, SigmaAldrich, USA
 Poloxamer 407, Sigma-Aldrich Co., USA
 Poloxamer 188, Sigma-Aldrich Co., USA
 Tween 80, Sigma-Aldrich Co., USA
 Praziquantel, Sigma-Aldrich Co., USA
 L- Leucine, Fluka, Switzerland
 Sucrose, Fluka, Switzerland
 N-hydroxysuccinamide (NHS), Sigma-Aldrich Co., USA
 1-Ethyl-3-(dimethylaminopropyl) carbodiimide hydrochlo- ride (EDC), SigmaAldrich Co., USA
 Tris-HCl, Bio-Rad , Richmond, CA, USA
 Sephadex A-50 powder, Amersham Bioscience, Uppsala, Sweden
 Sephacryl S-100 HR, Amersham Bioscience, Uppsala, Sweden
 30x2.5 cm Column, Biorad
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 Coomassie brilliant blue G-250 dye Bradford Dye, Bio-Rad, Richmond, CA, USA
 Nitrocellulose membrane, Millipore, Billerica, MA, USA
 Rabbit-anti-mouse secondary antibody, Imgenex Corporation, San Diego, USA
 TMB Liquid Substrate System – Sigma-Aldrich Company Ltd, Gillingham, UK
 Sodium acetate buffer pH 4.8, Sigma Aldrich, USA
 Caprylic acid (Octanoic acid) best grade, Sigma Aldrich, USA
 O-phenylene diamine dihydrochloride (OPD), Sigma Aldrich, USA
 Microtiter plates, Costar, Corporate Headquarters, Cambridge, MA, USA
 Roswell Park Memorial Institute (RPMI-1640) with l-glutamine, Life Biosciences
 Fetal Bovine Serum (FBS), Sigma Aldrich, USA
 100 IU/ml Penicillin, 100 µg/ml Streptomycin, Life Biosciences
 Gentamycin, Life Biosciences
 Sterile, flat-bottom, 24-well plates, Corning, NY, USA
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Appendix II: Equipment
 Ultraturrax T25 laboratory Emulsifier /Homogenizer, Ika, Staufen, Germany
 Qsonica Q700 Probe Sonicator, Qsonica, LLC., Newtown, USA
 Vortex, Fisher Scientific, Malaysia
 Magnetic Stirrer, Fisher Scientific, Malaysia.
 Ultra-Centrifugation with cooling unit, Sorvall RC 6 plus Centrifuge
 Lyophilizer, Labconco Corporation, Kansas City, MO
 Rotary evaporator, BUCHI R114, BÜCHI Labortechnik AG, Switzerland
 Particle size analyzer (Zetasizernano ZS), Malvern Zetasizer, Malvern Instruments Ltd.,
Malvern, UK

 Digital Balance, SI 234, Denver instrument, USA
 ELISA plate Reader, Synergy HT, BioTek Instruments Inc., Winooski, Vermont
 UV Spectrophotometer (Perkin-Elmer Lambda 1A)
 Cooling Centrifuge, Eppendorf Centrifuge 5415
 Epson Perfection 1640SU scanner, Tokyo, Japan
 Perfusion Pump MasterFlex pump, Cole-Parmer, Vernon Hills, Illinois
 Light microscope, Olympus Inverted Microscope Model IX70; Olympus, Tokyo, Japan
 Ziess Scanning Electron Microscope model
 Vecco Atomic Force Microscope
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Appendix III: Tables
Table 1.1: Summary of the Studied Factors Affecting the Properties of PLGA NPs in the Preliminary Study (Study I):
Various Formulae and their Composition.
Expt.
Studied Factor
#

I -1

Organic Solvent
Type
(Preparation
Method)

Variables

P1

DCM (ESE)

P4

Rotavap

P5

Stirring Under Atmospheric Conditions

Stirring at RT overnight

P6
P7
P8
P9
P10

2
4
6
12
Ultracentrifugation

Evaporation for 2 hours
Evaporation for 4 hours
Evaporation for 6 hours
Evaporation for 12 hours
Ultracentrifugation (20000 rpm, 4 C, 20 min, washing twice)

P11

Centrifugation

Centrifugation (11000 rpm, 4 C, 30 min, washing twice)

P12

Absence

No antiaggregant in the external aqueous phase

P13

Presence

0.01% leucine as antiaggregant in the external aqueous phase

P14

Homogenization

Homogenization only at 22,000 rpm for 20 min

P15

Sonication

P16

Homogenization and Sonication

**

P2

**

Evaporation
Technique

I-3

Evaporation time
(Hours)

I-4

Purification
Technique

I-5

Addition of
Antiaggregant in
Aqueous Phase

I-6

Emulsification
Technique

Experimental Conditions
Homogenization only at 22,000 rpm for 20 min, Rotavap,
Ultracentrifugation, No leucine in the external aqueous phase
Homogenization at ascending speed (5000, 10000 and 20000 rpm - 3
min each). Then, homogenization only at 22,000 rpm for 3 min,
Rotavap, Ultracentrifugation, No leucine in the external aqueous phase
Stirring at 800rpm for 24hrs at RT, Ultracentrifugation, No leucine in
the external aqueous phase
o
Rotavap at 45 C for 20 min

P3
I-2

*

F#

EA (ESD)
Acetone (Nanopptn)

o

o

Continueous Sonication using probe sonicator only at 100% amplitude
for 20 min
Homogenization at ascending speed (5000, 10000 and 20000 rpm - 3
min each). Then, probe sonication (pulse on 30 sec and pulse off 5 sec)
for 20 min
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Expt.
Studied Factor
#

I-7

I-8

Sonication Time

Effect of
Lyophilization

*

F#

Variables

P17

20 min

P18

10 min

P19

5 min

P20

Not Lyophilized

Experimental Conditions
Homogenization at ascending speed (5000, 10000 and 20000 rpm - 3
min each). Then, probe sonication (pulse on 30 sec and pulse off 5 sec)
for 20 min
Homogenization at ascending speed (5000, 10000 and 20000 rpm - 3
min each). Then, probe sonication (pulse on 30 sec and pulse off 5 sec)
for 10 min
Homogenization at ascending speed (5000, 10000 and 20000 rpm - 3
min each). Then, probe sonication (pulse on 30 sec and pulse off 5 sec)
for 5 min
No lyophilization
o

Freeze drying at -80 C and <10 mm mercury pressure for 48 hours after
Lyophilized
P21
addition of 0.2% sucrose as cryoprotectant
* Fixed levels of other factors throughout all experiments of this study are: PLGA 75:25 5% w/v, Organic Solvent 5% v/v (DCM in all formulae
except P2 and P3), PVA 1% w/v, D:P (1:6), Initial Drug Weight (50mg)
** For P2 and P3 refer to sections I.A.1.2 and I.A.1.3 respectively.
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Table 1.2: Summary of the Studied Factors Affecting the Properties of PLGA NPs in the Screening Phase (Study II): Various Formulae and their
Composition.
Expt. Number
Screened Variable
F#
Levels*
1%
S1
Polymer Concentration
2.5%
II-1
S2
5%
S3
1%
S4
Organic Solvent %
2.5%
II-2
S5
5%
S6
Poloxamer 407
S7
TW 80
S8
SAA Type
II-3
Poloxamer 188
S9
PVA
S10
* Fixed levels of other factors throughout all experiments of this study are: PLGA 75:25 , DCM, SAA 1% w/v, Non-medicated

Table 1.3: Summary of the Studied Factors Affecting the Properties of PLGA NPs in the Validation Phase I (Study III): Various Formulae and their
Composition.
Expt. Number
Validation Using (Polymer Type/ Characteristics)
F#
Formula Type
Blank
VI1
PLGA 75:25
III-1
(M.wt. 17,000 Da "0.2 dl/g inherent viscosity", Uncapped)
PZQ - Loaded
VI2
Blank
VI3
PLGA 50:50
III-2
(M.wt. 44,000 Da "0.4 dl/g inherent viscosity", Uncapped)
PZQ - Loaded
VI4
Fixed levels of other factors throughout all experiments of this study are: PLGA 5% w/v, DCM 5% v/v, PVA 1% w/v, D:P (1:6)
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Table 1.4: Summary of the Studied Factors Affecting the Properties of PLGA NPs in the Optimization Phase (Study IV): Various Formulae and their
Composition.
Expt. Number
Optimized Variable
F#
Levels
0.5 %
O1
1%
O2
SAA %
IV -1
2%
O3
4%
O4
NaCl
O5
Addition of Salt to External/Aqueous Phase (Salt Type)
IV -2
(NH4)2 SO4
O6
5
O7
Addition of Salt to External/Aqueous Phase (Salt %)
10
IV -3
O8
20
O9
1:1
O10
1:2
O11
D:P
1:6
IV-4
O12
1:8
O13
1:10
O14
Fixed levels of other factors throughout all experiments of this study are: PLGA 50:50 5% w/v, DCM 5% v/v, PVA
Table 1.5: Summary of the Studied Factors Affecting the Properties of PLGA NPs in the Validation Phase II (Study V): Various Formulae and their
Composition.
Formulae Prepared using selected optimum levels of the investigated
Expt. Number
F#
Formula Type
parameters
Blank
VII1
1:1 (50mg)
VII2
1:1 (Effect of Initial Drug Weight)
V-1
Blank
VII3
1:1 (100mg)
VII4
Blank
VII5
1:2 (50mg)
VII6
1:2 (Effect of Initial Drug Weight)
V-2
Blank
VII7
1:2 (100mg)
VII8
Fixed levels of other factors throughout all experiments of this study are: PLGA 50:50 5% w/v, DCM 5% v/v, PVA 0.5% w/v, (NH4)2 SO4 5% w/v
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Table 1.6: Concentrations of Praziquantel Used for Establishment of Calibration Curve Using HPLC Metthod.
Concentration (µg/ml)

AUC average

±SD

2

12.741

0.685

4

26.452

0.1

7

43.201

0.456

10

63.244

0.1

13

83.174

0.277

15

94.585

1.75
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Study I: Preliminary Phase

Table 1.7: Different Characteristics of PZQ-loaded PLGA NPs Formulations Prepared in the Preliminary Study (Study I). Results were represented
as Mean±SD of three independent experiments.
Particle Size
Zeta-potential
PDI
EE%
DL%
nm
mV
Phase
Expt #
F#
Variable
Mean (±SD) Mean (±SD) Mean (±SD) Mean (±SD) Mean (±SD)
DCM (ESE)
281.3 3.98 0.61 0.093 -28.5 4.23
4.2 0.85 0.6 0.85
P1
EA (ESD)
341.83 9.4 0.71 0.241 -26.93 2.98 4.15 0.99 0.592 0.99
I -1
P2
Acetone (Nanopptn)
96.71 4.8 0.59 0.19 -26.37 3.67
2.7 1.13 0.385 1.13
P3
Rotavap
281.3 3.98 0.61 0.23 -28.5 4.23
4.2 0.85 0.6 0.85
P4
I-2
Stirring Under Atmospheric Conditions 290.8 2.82 0.57 0.19 -27.99 2.91 2.13 1.45 0.304 1.45
P5
2
249.6 3.33 0.52 0.21 -26.1 1.31 4.27 2.46 0.61 2.46
P6
4
265.8 4.08 0.42 0.156 -27.27 2.56 3.75 1.21 0.53 1.21
P7
I-3
6
272 3.83 0.48 0.27 -27.27 1.89 3.23 2.95 0.46 2.95
P8
12
290.8 2.82 0.57 0.19 -27.99 2.91 2.13 1.45 0.304 1.45
P9
Ultracentrifugation
249.6 3.33 0.52 0.21 -26.1 1.31 4.27 2.46 0.61 2.46
P10
I-4
Centrifugation
241.1 2.67 0.38 0.13 -25.2 1.78 4.95 2.11 0.707 2.11
P11
Absence
241.1 2.67 0.38 0.13 -25.2 1.78 4.95 2.11 0.707 2.11
P12
I-5
Presence
239.2 1.87 0.29 0.11 -24.9 1.33 4.78 1.9 0.682 1.9
P13
Homogenization
239.2 1.87 0.29 0.11 -24.9 1.33 4.78 1.9 0.682 1.9
P14
Sonication
230.74 2.11 0.583 0.155 -25.11 2.9
4.39 3.9 0.627 3.9
I-6
P15
Homogenization and Sonication
222.97 2.09 0.07 0.09 -26.08 4.1
4.31 4.5 0.615 4.5
P16
20 min
222.97 2.09 0.07 0.09 -26.08 4.1
4.31 4.5 0.615 4.5
P17
10 min
246.63 3.86 0.321 0.095 -26.73 5.21 5.28 3.67 0.754 3.67
I-7
P18
5 min
280.3 3.98 0.509 0.085 -25.91 5.17 4.97 2.71 0.71 2.71
P19
Not Lyophilized
222.97 2.09 0.07 0.09 -26.08 4.1
4.31 4.5 0.615 4.5
P20
I-8
Lyophilized
227.23 4.8 0.12 0.04 -27.84 3.19 4.07 3.73 0.581 3.73
P21
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Study II: Screening Phase

Table 1.8: Different Characteristics of PZQ-loaded PLGA NPs Formulations Prepared in the Screening Phase (Study II). Results were represented as
Mean±SD of three independent experiments.
Particle Size
Zetapotential
PDI
nm
mV
Phase
Expt #
F#
Variables
Mean (±SD) Mean (±SD) Mean (±SD)
1% PLGA
214.33 4.09 0.38
0.1 -24.65 2.8
S1
2.5% PLGA
218.17 7.57 0.28 0.08 -26.11 1.1
II-1
S2
5% PLGA
225.77 0.92 0.09 0.02 -29.39 3.9
S3
1% DCM
290.3 3.75 0.49
0.1 -23.67 3.1
S4
2.5% DCM
262.7 2.71 0.33 0.09 -25.98 2.8
II-2
S5
5% DCM
225.77 0.92 0.09 0.02 -29.39 3.9
S6
Poloxamer 407
448.22 8.6
0.53
0.1 -27.8 2.8
S7
TW 80
545.97 7.3
0.89 0.08 -28.1 4.9
S8
II-3
Poloxamer 188
361.57 6.95 0.47 0.08 -27.3 3.4
S9
PVA
225.77 0.92 0.09 0.02 -29.39 3.9
S10

Study III:
Validation Phase I

Table 1.9: Different Characteristics of PZQ-loaded PLGA NPs Formulations Prepared in the Validation Phase I (Study III). Results were represented
as Mean±SD of three independent experiments.
Particle Size
Zetapotential
PDI
EE%
DL%
Expt
nm
mV
Phase
F#
Variable
#
Mean ±SD Mean ±SD Mean ±SD Mean ±SD Mean ±SD
PLGA
75:25
225.77
0.92 0.09 0.02 -29.39 3.9 NA NA NA NA
VI1
(M.wt. 17,000 Da "0.2 dl/g inherent viscosity",
III-1
222.97 2.09 0.07 0.09 -26.08 4.1 4.31 4.5 0.615 4.5
VI2
Uncapped)
206.6 0.72 0.07 0.03 -25.9 0.92 NA NA NA NA
VI3
PLGA 50:50
(M.wt. 44,000 Da "0.4 dl/g inherent viscosity",
III-2
214.73 1.43 0.05 0.02 -24.5 0.62 8.08 1.1 1.15 1.1
VI4
Uncapped)
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Table 1.10: Different Characteristics of PZQ-loaded PLGA NPs Formulations Prepared in the Optimization Phase (Study IV). Results were
represented as Mean±SD of three independent experiments.

Phase Expt #

F#

Variable

Particle Size
nm

PDI

Zetapotential
mV

EE%

DL%

Mean ±SD Mean ±SD Mean ±SD Mean ±SD Mean ±SD

Study IV: Optimization Phase

IV -1

IV -2

IV -3

IV-4

O1

0.5 % PVA

229.3 2.46

0.04

0.03 -24.83 0.10 10.39 1.65

1.47

1.65

O2

1% PVA

214.73 1.43

0.05

0.02

-24.5

0.62

8.08

1.1

1.15

1.1

O3

2% PVA

2.5

0.07

0.03

-20.6

0.15

7.58

1.21 1.082 1,21

O4

4% PVA

188.57 5.63

0.15

0.08

-18.3

0.89

4.15

3.09 0.592 3.09

O5

NaCl

240.1 4.95

0.18

0.02 -24.57 0.32 27.22 1.17

3.95

1.17

O6

(NH4)2 SO4

232.3 3.18

0.19

0.01

-21.9

0.4

26.33

1

3.81

1

O7

5% (NH4)2 SO4

232.3 3.18

0.19

0.01

-21.9

0.4

26.33

1

3.81

1

O8

10% (NH4)2 SO4

610.1 6.56

0.58

0.07 -22.23 1.12 65.38 1.58

9.29

1.58

O9

20% (NH4)2 SO4

608.2

4.7

0.58

0.12 -21.93 1.86

99.9

5

14.27

5

O10

D:P (1:1)

193.6 1.89

0.09

0.01 -21.78 0.89

37.9

2.1

12.63

2.1

O11

1:2

200.3 2.75

0.18

0.02 -24.21 1.23 21.65

2.1

7.216

2.1

O12

1:6

214.73 1.43

0.05

0.02

-24.5

0.62

8.08

1.1

1.15

1.1

O13

1:8

236.8 4.93

0.11

0.03 -26.27

0.5

6.95

2.76 0.772 2.76

O14

1:10

237.2 2.66

0.15

0.01

1.17

3.65

5.43 0.331 5.43

213
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-28.5

Table 1.11: Different Characteristics of PZQ-loaded PLGA NPs Formulations Prepared in the Validation Phase II (Study V). Results were
represented as Mean±SD of three independent experiments.

Expt
Phase
#

Particle Size
nm
F#

PDI

Variable

Zetapotentia
l
mV

EE%

DL%

Study V: Validation Phase II

Mean ±SD Mean ±SD Mean ±SD Mean ±SD Mean ±SD
185.9 4.04

0.1

0.01 -24.57 0.32

200.1 4.68

0.19

0.02 -21.4

VII3

187.43 2.78

0.05

0.01 -23.98 2.98

VII4

200.8 4.02

0.13

0.08 -21.03 3.08 94.19 3.46 47.095 3.46

VII5

192.8 4.09

0.12

0.01 -27.5

1.73

204.8 3.89

0.09

0.05 -25.9

2.99 45.77 1.98 15.255 1.98

201.4 3.46

0.15

0.03 -28.1

2.34

0.14

0.01 -25.4

1.61 66.95 1.63 22.52 1.63

VII1
VII2

NA

NA

NA

NA

2.10 77.16 2.05 38.59 2.05

1:1 (Effect of Initial Drug Weight)

V-1

VII6

NA

NA

NA

NA

NA

NA

NA

NA

1:2 (Effect of Initial Drug Weight)

V-2
VII7
VII8

205
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4.81

NA

NA

NA

NA

Table 1.12: Release Profile of PZQ (Cumulative % Release Over Time) from the optimized Formula VII4 in Comparison with Pure PZQ Powder. Data was
present as Mean±SD of triplicate experiment.
Time

Hours

Days

0.25
0.5
0.75
1
2
3
6
9
12
1
2
3
7
14
21
28
35

PZQ Cumulative Release
±SD
VII4
3.15
10.64
4.21
10.57
4.97
14.77
6.15
16.68
3.85
24.42
1.87
32.61
3.76
47.99
2.97
49.9
3.11
54.99
2.02
54.21
4.68
63.44
3.91
63.77
1.76
63.67
2.67
62.46
4.05
67.98
2.99
72.69
1.67
79.82

Control
10.86
13.14
21.84
28.48
36.32
44.78
62.49
67.54
77.96
93.77
94.97
95.85
91.63
91.43
93.89
94.67
94.21
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±SD
4.08
3.79
4.32
2.98
2.67
3.05
4.19
5.01
4.29
2.88
3.43
1.93
4.09
2.74
3.99
1.89
2.45

Table 2.1: Optimum PZQ - loaded PLGA NPs prepared by the optimized ESE method.

Internal Organic Phase
F#

External Aqueous Phase

Particle
Size
nm

PDI

Zetapotential
mV

EE%

DL%

Initial
Organic Organic
Aqueous
SAA
Salt
Polymer
Drug
SAA
Salt
Solvent Solvent D:P
Solvent
%
% Mean ±SD Mean ±SD Mean ±SD Mean ±SD Mean ±SD
% w/v
Weight
Type
Type
Type % v/v
% v/v
w/v
w/v
mg

VII3

5%

DCM

5%

NA

NA

95%

PVA 0.5%

(NH4)2
5% 187.43 2.78 0.05 0.01 -23.98 2.98
SO4

VII4

5%

DCM

5%

1:1

100

95%

PVA 0.5%

(NH4)2
5% 200.8 4.02 0.13 0.08 -21.03 3.08 94.19 3.46 47.095 3.46
SO4

NA NA

NA NA

Table 2.2: Different Variables of Two Studied Parameters for Preparation of Immuno- NPs Formulations surface-functionalized via Physical
Adsorption of pAb.

Physical Adsorption

Coating
Method

Expt. #

Parameter

I-1

Time of
Adsorption
(5µg pAb)

I-2

Amount of
Antibody
(pAb : PLGA)
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F#

Formula Type

A1
A2
A3
A4
A5
A6
A7
A8
A9

Control
pAb*
Control
pAb*
Control
pAb
pAb
pAb
pAb

Variables
12 Hours
24 Hours
No pAb
5 µg (1:100)
10 µg (1:50)
20 µg (1:25)
500 µg (1:1)

Table 2.3: Immuno- NPs Formulations surface-functionalized through Chemical Conjugation of pAb via EDC/NHS Carbodiimide Chemistry.

Chemical
Conjugation

Coating
Method

Expt. #

II-1

Parameter

F#

Amount of
Antibody
(pAb : PLGA)

C1
C2
C3
C4
C5

Formula
Type
Control
pAb
pAb
pAb
pAb

Variables
No pAb
5 µg (1:100)
10 µg (1:50)
20 µg (1:25)
500 µg (1:1)

Table 2.4: Concentrations Used for BSA Standard Curve Construction and the Measured Absorbance at 595 Using Bradford Protein Quantification
Assay. Results were represented as Mean±SD of triplicate measurements.
Concentration
(µg/ml)
2000
1500
1000
750
500
250
125
25

25
20
10
5
2.5

Absorbance at 595nm
Mean
±SD
1.321
0.110
1.159
0.041
0.782
0.003
0.639
0.015
0.484
0.016
0.236
0.014
0.121
0.018
0.023
0.024

0.7022
0.5985
0.281567
0.093067
0.106767

0.025322
0.015938
0.007047
0.005558
0.020951
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K
1513.546
1294.48
1278.881
1173.219
1032.631
1061.121
1029.937
1101.322

35.60239
33.41688
35.51557
53.72493
23.41555

Table 2.5: Reactivity of Purified Target S. haematobium CP antigen Determined by Indirect ELISA. Results were expressed as Mean±SD of 3
measurements.
Serum Samples
Absorbance at 492 nm "Mean (± SD)"
1.41 (0.09)
Schistosomiasis (S. haematobium)
0.12 (0.076)
Fascioliasis
0.18 (0.092)
Ascariasis

Table 2.6: Reactivity and Specificity of Anti-S.haematobium CP IgG pAb Against Different Parasitic Antigens by Indirect ELISA. Results were
expressed as Mean±SD of 3 measurements.
Parasitic Antigen
Schistosomiasis (S. haematobium)
Fascioliasis
Ascariasis

Absorbance at 492 nm "Mean (± SD)"
2.37 (0.12)
0.21 (0.11)
0.27 (0.08)

Table 2.7: Surface coating of optimum PZQ - loaded PLGA NPs by physical adsorption of pAb: Various Immuno-NPs Characteristics. Results were
expressed as Mean±SD of triplicates.

Physical Adsorption

Coating
Method

Expt. #

I-1

I-2

Formula
Parameter F#
Variables
Type
A1 Control
Time of
A2 pAb*
Adsorption
Control
(5µg pAb) A3
A4 pAb*
A5 Control
Amount of A6 pAb
Antibody
A7 pAb
(pAb :
A8 pAb
PLGA)
A9 pAb

12 Hours
24 Hours
No pAb
5 µg (1:100)
10 µg (1:50)
20 µg (1:25)
500 µg (1:1)

pAb
Adsorption
(%w/w of
PLGA weight)
Mean ±SD
0
0
0.374 0.283
0
0
0.381 0.176
0
0
0.374 0.412
0.736 0.409
2.38 0.367
64.2 3.91
80

Adsorption
Efficiency
%
Mean
0
37.4
0
38.1
0
37.4
36.8
59.5
64.2

±SD
0
2.99
0
2.05
0
5.01
1.99
3.09
2.87

Particle
Size
nm
Mean ±SD
198.9 3.04
207.2 3.87
199.1 4.56
209.08 3.49
198.9 4.21
207.2 4.98
211.76 3.02
210.21 3.71
218.23 3.03

PDI
Mean
0.09
0.19
0.16
0.18
0.09
0.19
0.18
0.18
0.15

±SD
0.026
0.02
0.051
0.1
0.082
0.065
0.068
0.09
0.21

Zetapotential
mV
Mean
-22.01
-11.32
-21.3
-10.19
-22.01
-11.32
-11.12
-11.7
-10.34

±SD
0.72
1.99
0.91
2.81
2.47
2.94
2.1
3.01
2.57

EE%
Mean ±SD
91.21 4.01
91.89 4.19
86.82 4.48
87.02 3.39
91.21 3.1
91.89 4.2
90.91 3.31
91.32 3.19
90.89 4.19

Table 2.8: Surface coating of optimum PZQ - loaded PLGA NPs by Chemical Conjugation of pAb via Carbodiimide Reaction: Various Immuno-NPs
Characteristics. Results were expressed as Mean±SD of triplicates.

Chemical
Conjugation

Coating Expt.
Formula
Parameter F#
Variables
Method #
Type

Amount
of
II-1 Antibody
(pAb :
PLGA)

C1 Control No pAb
pAb 5 µg (1:100)
C2
pAb 10 µg (1:50)
C3
pAb 20 µg (1:25)
C4
pAb 500 µg (1:1)
C5

pAb
Conjugation
(%w/w of
PLGA
weight)
Mean ±SD
0
0
0.784 0.21
1.59 0.278
3.26 1.98
89.31 3.1

Conjugation
Particle Size
Efficiency
nm
%
Mean
0
78.4
79.8
81.65
89.31

±SD
0
1.64
2.39
2.29
1.78

Mean
202.1
637.2
616.98
230.4
222.78

PDI

Zetapotential
mV

EE%

±SD Mean ±SD Mean ±SD Mean ±SD
3.15 0.11 0.089 -21.97 1.89 88.96 4.89
8.12 0.42 0.092 -16.7 1.45 88.5 4.19
10.1 0.398 0.2 -18.1 2.72 88.71 5.01
4.19 0.19 0.063 -12.2 3.1 88.67 2.67
4.56 0.16 0.046 -11.98 2.27 89.43 3.92

Table 2.9: Summary of Various Physical Properties of the Optimized Uncoated PZQ- loaded PLGA NPs and pAb- Coated NPs. Data were expressed
as Mean±SD (n=3).
PZQ- loaded PLGA NPs
VII4
Particle Size nm
PDI
Zetapotential mV
EE%

Mean
200.8
0.13
-21.03
94.19

±SD
4.02
0.08
3.08
3.46

pAb- coated PLGA NPs
(Adsorption)
A9
Mean
±SD
218.23
3.03
0.15
0.21
-10.34
2.57
90.89
4.19
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pAb- coated PLGA NPs
(Conjugation)
C5
Mean
±SD
222.78
4.56
0.16
0.046
-11.98
2.27
89.43
3.92

Appendix IV: Figures

Figure 1: Global distribution of schistosomiasis.9 (Reproduced with Permission “Appendix
V”)
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Figure 2: Schistosome Parasite Life Cycle. 131, 132
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Figure 1.1: Various Formulation Parameters Studied for Controlling the Properties PZQloaded PLGA Nanoparticles.
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Figure 1.2: Five Main Studies in “Chapter One” for Optimization of the Formulation and
Experimental Parameters for the Preparation of PLGA NPs.

Figure 1.3: Schematic Representation of Different Preparation Methods of PLGA NPs. (a)
Emulsification- Solvent Evaporation Technique. (b) Emulsification – Solvent Diffusion
Technique. (c) Solvent Displacement Technique. (d) Summary of the three methods.52,53
(Reproduced with Permission “Appendix V”)
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Figure 1.4: Schematic Representation of the used Single (O/W) Emulsion- Solvent
Evaporation Method for Preparation of PZQ- loaded PLGA NPs . (a) Scheme of the Different
Steps62, (b) Sketch illustrating the Formation of NPs.57 (Reproduced with Permission
“Appendix V”)

Figure 1.5: Praziquantel Standards Calibration Curve Constructed Using HPLC Method

86

Figure 1.6: HPLC Chromatogram Showing (a) the Characteristic Peak of PZQ at Retention
Time 3.172 minutes (PZQ Standard 500µg/ml), (b) PLGA Separation at Retention Time
around 1.2 minutes and PZQ reading at Retention Time around 3.2 minutes Indicating No
interference between the drug and the polymer at Wavelength 262nm.

Figure 1.7: Bar Charts Comparing Between the Various Formulations Prepared in the
Preliminary Study (Study I). (a) Particle Diameter, nm and Size Distribution, PDI. (b)
Zetapotential, mV. (c) Encapsulation Efficiency and Drug Loading %. Data were represented
as Mean±SD (n=3)
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Figure 1.8: Bar Charts Comparing Between the Various Formulations Prepared in the
Screening Phase (Study II). (a) Particle Diameter, nm and Size Distribution, PDI. (b)
Zetapotential, mV. Data were represented as Mean±SD (n=3)

Figure 1.9: Bar Charts Comparing Between the Various Formulations Prepared in the
Validation Phase I (Study III). (a) Particle Diameter, nm and Size Distribution, PDI. (b)
Zetapotential, mV. (c) Encapsulation Efficiency and Drug Loading %. Data were represented
as Mean±SD (n=3)
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Figure 1.10: Bar Charts Comparing Between the Various Formulations Prepared in the
Optimization Phase (Study IV). (a) Particle Diameter, nm and Size Distribution, PDI. (b)
Zetapotential, mV. (c) Encapsulation Efficiency and Drug Loading %. Data were represented
as Mean±SD (n=3)

Figure 1.11: Type of biodegradable nanoparticles: According to the structural organization
biodegradable nanoparticles are classified as nanocapsule, and nanosphere. Most of the drug
is entrapped inside the polymer and small part of it is adsorbed on the surface.52 (Reproduced
with Permission “Appendix V”)
89

Figure 1.12: Bar Charts Comparing Between the Various Formulations Prepared in the
Validation Phase II (Study V). (a) Particle Diameter, nm and Size Distribution, PDI. (b)
Zetapotential, mV. (c) Encapsulation Efficiency and Drug Loading %. Data were represented
as Mean±SD (n=3)

Figure 1.13: DSC Thermogram of Pure PLGA, PVA, Free PZQ, Physical Mixture of PZQ
and PLGA, Physical Mixture of PZQ and PVA and PZQ- loaded PLGA NPs.
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Figure 1.14: FTIR Spectrum of Pure PLGA, PVA, Free PZQ, Physical Mixture of PZQ and
PLGA, Physical Mixture of PZQ and PVA and PZQ- loaded PLGA NPs.

Figure 1.15: Chemical Structure of Praziquantel. 133
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Figure 1.16: Release Profile of PZQ from the optimized Formula VII4 in Comparison with
Pure PZQ Powder. Data was present as Mean±SD of triplicate experiment.

Figure 1.17: Degradation and Hydrolysis of PLGA Nanoparticles. Biologically, the
degradation products, lactic and glycolic acids, will be metabolized in Citric Acid “Krebs”
Cycle.52 (Reproduced with Permission “Appendix V”)
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Figure 1.18: Optical Microscope. (Optimum Formula VII4, 40X Magnification)

Figure 1.19: Scanning Electron Micrograph of the optimum PZQ- loaded PLGA NPs
Formula (VII4).
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Figure 1.20: Scanning Electron Micrograph of (a) Formula S7 prepared using Poloxamer
407, (b) Formula P3 Prepared by Nanoprecipitation Using Acetone as Organic Solvent, (c)
Formula O9 prepared Using 20% Ammonium Sulphate in External Phase, and (d)
Lyophilized NPs of Formula P21.

Figure 1.21: Two-dimensional (a) and Three-dimensional (b) AFM topographic images of
Optimum PZQ- loaded PLGA Formula VII4.
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Figure 2.1: Basic Principle of Ion exchange chromatography. (Modified from134)

Figure 2.2: Basic Principle of Gel Filtration (Size Exclusion) Chromatography. (Modified
from 135)
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Figure 2.3: Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS –PAGE) Gel
Setup. (Modified from136 )

Figure 2.4: Basic Principle of Indirect ELISA. 137

96

Figure 2.5: Basic Principle of Dot Blot (Indirect- Type Immunoassay). 138

Figure 2.6: Fractions of Antigens after Purification of E/S Crude Products by Ion Exchange
Chromatography on DEAE Sephadex A-50 Column.
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Figure 2.7: Fractions of Antigens after Gel Filtration Chromatography on Sephacryl S-100
HR Column.

Figure 2.8: BSA Calibration Curve. (a) Concentration Range: 0-2000µg/ml, (b)
Concentration Range: 0-25g/ml.
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Figure 2.9: SDS-PAGE Gel Profile of Adult S. haematobium Worm Antigen Fractions
Eluted from Different Chromatography Columns
1: Low molecular weight standard protein.
2: Crude E/S product.
3: Fraction containing target CP antigen partially purified on DEAE Sephadex A-50 column.
4: Fraction containing target purified CP antigen eluted from Sephacryl S-100 HR column.

99

Figure 2.10: Reactivity of immunized rabbit anti- S. haematobium CP antisera (pAb) against
S. haematobium CP Antigen by Indirect ELISA.

Figure 2.11 :Fractions of Rabbit Anti- CP pAb after Purification by Ion Exchange
Chromatography on DEAE Sephadex A-50 Column.
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Figure 2.12: SDS-PAGE Gel Profile of Anti- S. haematobium IgG pAb before and after
purification
1: Low molecular weight of standard protein.
2: Crude anti- S. haematobium CP pAb (before purification).
3: Precipitated proteins after 50% ammonium sulfate treatment.
4: Partially purified IgG-pAb after 7% caprylic acid treatment.
5: Purified IgG-pAb after ion exchange chromatography.

Figure 2.13: General Structure of an Antibody.62 (Reproduced with Permission “Appendix
V”)
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Figure 2.14: Comparison between Different Immuno-NPs Formulations Surface- Coated via
pAb Adsorption Method with regards to Adsorption Efficiency % and the Amount of
Adsorbed pAb per mg of PLGA.

Figure 2.15: Bar Charts Comparing the Physical Properties of Various pAb-Adsorbed
PLGA NPs Formulations. (a) Mean NPs Size “nm” and Size Distribution “PDI”, (b)
Zetapotential “mV”, and (c) Encapsulation Efficiency %.
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Figure 2.16: Comparison between Different Immuno-NPs Formulations Surface- Coated via
pAb Chemical Conjugation Method with regards to Conjugation Efficiency % and the
Amount of Conjugated pAb per mg of PLGA.

Figure 2.17: Bar Charts Comparing the Physical Properties of Various pAb-Conjugated
PLGA NPs Formulations. (a) Mean NPs Size “nm” and Size Distribution “PDI”, (b)
Zetapotential “mV”, and (c) Encapsulation Efficiency %.
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Figure 2.18: Scheme illustrating EDC/NHS Carbodiimide Crosslinking Reaction. (Modified
from139 )

Figure 2.19: Bar Charts Comparing the Physical Properties of the Three Optimized PLGA
NPs Formulations. (a) Mean NPs Size “nm” and Size Distribution “PDI”, (b) Zetapotential
“mV”, and (c) Encapsulation Efficiency %.
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Figure 2.20: Nitrocellulose Membrane Showing the Dot Blot Indirect Immunoassay. Scores:
(0) No Bioactivity, (1) Weak, (2) Medium, and (3) Strong Bioactivity.
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Improvement of Antischistosomal Activity of Praziquantel by Incorporation
into Poly (D,L lactide-co-glycolide) (PLGA) Nanoparticles
E. R. Abdul-Ghany 1, R. O. Ahmed 2, G. A. Awad 2, S. K. Zada 1
School of Science and Engineering, American University in Cairo, Cairo, Egypt , 2 Faculty of Pharmacy, Ain Shams University, Cairo, Egypt

Results and Discussion

Introduction

 Praziquantel (PZQ) is the drug of choice for treatment of
schistosomiasis since its discovery in 1975. PZQ is not only used
for treatment of schistosomiasis, but it is also used for control of
other parasitic diseases and it is included on the Model List of
Essential Medicines of WHO.

 Preparation of PLGA NPs encapsulated with PZQ : This was
done using single (O/W) Emulsion-Solvent Evaporation (ESE)method
(Fig. 2).
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 Experimental Design: various formulation and process
parameters were investigated and optimized namely: drug:
polymer ratio, surfactant concentration and osmotic effect of
adding salts to the external aqueous phase (salt type and salt
concentration).
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(a: Particle Size and PDI, b: EE% )%) (F1: PLGA 50:50*, F2: PLGA 75:25, F3, F4 and F5: 2%, 1% and 0.5% SAA% respectively, F6
and F7:5% NaCl and 5% (NH4)2SO4 in external aqueous phase respectively, F8, F9 and F10: 5%, 10% and 20% (NH4)2SO2 in
external aqueous phase, F11 to F15: Drug to polymer ratio: 1:10, 1:8, 1:6 , 1:2 and 1:1 respectively, F16**: Medicated optimum
formulation prepared after different parameter optimization, F17: Blank optimum formulation.)

c

d

50:50 was selected for preparation of F3 to F16.
variables for preparation of F16 were D:P (1:1), SAA% (0.5%), (NH4)2SO2 (5%).

**Selected

•
•
•
•
•

PLGA 50:50 doubled EE% when compared with using PLGA 75:25. (F1 & F2)
Reducing SAA% increased EE%. (F3, F4 & F5)
Addition of salts to the external aqueous phase increased EE%. (NH4)2SO2 resulted in more stable
emulsion. (F6 & F7)
Lower concentration of (NH4)2SO2(5%) increased EE% while keeping the optimized size and PDI
unchanged. (F8, F9 & F10)
D:P 1:1 increased the EE% to a great extent. (F11 to F15)
Fig. 4: Characterization of Optimized PZQ loaded PLGA NPs (F16) and Blank PLGA NPs (F17).
(a: c: Charge, b: In vitro Release Profile***c: SEM and d: AFM)
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 In vitro parasitological studies were conducted to compare
the schistosomicidal effect of PZQ and PZQ-PLGA NPs on
both juvenile and adult Schistosoma haematobium. Parasites
in different groups were examined after CO2 incubation for
72 hours in compound RPMI media to observe any
ultrastructural changes in their teguments using SEM.
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Fig. 2: Schematic representation of polymeric nanoparticles preparation through the high speed homogenization
-solvent evaporation method
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Fig. 3: Characterization of PZQ loaded PLGA NPs prepared by ESE: Effect of different experimental variables.
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 Characterization of PZQ-PLGA NPs:
 Particle size, Particle size distribution (PDI) and
ζ potential using dynamic light scattering method.
 Drug content of PZQ-loaded NPs and in-vitro drug release
rate using a validated HPLC method.
 Surface morphology using scanning electron microscopy
(SEM) and Atomic Force Microscopy (AFM).
 Physicochemical properties: DSC and FTIR
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 Aim of Work:
This study aimed at overcoming the inherent drawbacks of
PZQ through formulation, optimization and evaluation of
PZQ-loaded biodegradable PLGA nanoparticles (NPs) as a
preliminary study for design of functional nano-carriers that
specifically target and treat schistosomiasis.

Materials and Methods
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In Vitro release studies were conducted in phosphate buffered saline (PBS 7.4) at 37oC and 100 rpm. Sink conditions were maintained throughout the study.
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Fig. 11: Life Cycle of Schistosome Parasites.
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 However, PZQ suffers from several weaknesses. The main one is
its rapid and extensive first pass metabolism through the liver
resulting in 400-fold less active metabolites. In turn, this
necessitates the administration of high oral dose to achieve the
therapeutic drug concentration which represents a challenge in
drug development. In such scenario, nanoparticulate drug
delivery systems have a crucial role to play in improvement of
the current anti-parasitic agents.

Particle Size (nm)

 Schistosoma parasites (Fig. 1)
infect more than 200 million
people in about 74 countries
and about 600 million people
are at risk. According to WHO,
schistosomiasis is the second
most prevalent parasitic
disease worldwide that has
no effective vaccine yet.
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Fig. 6: Scanning Electron Micrographs showing the ultrastructural changes in the teguments of juvenile S. haematobium
(a: Negative Control “Untreated”, b: Positive Control “Treated with PZQ LC100”, c: PLGA NPs , d: PZQ-PLGA NPs)

Fig. 5: Physicochemical Properties of Optimized Formula F16 (a) FTIR and (b) DSC

Conclusion

• Spherical PLGA NPs with a smooth surface were prepared (Fig. 4c & 4d).
• The optimized formulation (F16) was 200.1±4.68nm in diameter with homogenous size distribution (PDI 0.19±0.02) (Fig. 3a) and a negatively charged
surface (-21.4±1.1mV) (Fig. 4a)
• Both DSC thermogram and FTIR spectrum showed the compatibility between PZQ and PLGA and encapsulation of the drug into the polymer (Fig. 5a and 5b)
• PZQ- loaded PLGA NPs showed a sustained release profile from the optimum formulation (Fig. 4b) with the highest encapsulation efficiency and drug
loading (77.49±2.47% and 38.59±2.47% respectively) (Fig. 3b) and a higher schistosomicidal effect (Fig. 6).
• PZQ-loaded PLGA NPs could be a potential preliminary delivery system for treatment of Schistosomiasis.
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Improvement of Antischistosomal Activity of Praziquantel (PZQ) by Incorporation into Poly (D,L
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Purpose
Praziquantel is the drug of choice for treatment of schistosomiasis since its discovery in 1975. According to WHO,
schistosomiasis is the second most prevalent parasitic disease worldwide that has no effective vaccine yet. Schistosoma
parasites infect more than 200 million people in about 74 countries and about 600 million people are at risk. PZQ is not only
used for treatment of schistosomiasis, but it is also used for control of other parasitic diseases and it is included on the Model
List of Essential Medicines of WHO. Parasitic diseases, despite their significant global burden, have been rather under
researched by drug discovery companies as compared to other diseases mainly due to complexities of parasitic infections and
lack of economic motivations. In such scenario, nanoparticulate drug delivery systems have a crucial role to play in
improvement of the current anti-parasitic agents. This study aims at overcoming the inherent drawbacks of PZQ through
formulation, optimization and evaluation of PZQ-loaded biodegradable PLGA nanoparticles (NPs) for treatment of
schistosomiasis.
Methods
PZQ was encapsulated in biodegradable PLGA NPs using single emulsion-solvent evaporation method. Various parameters
were investigated and optimized like drug: polymer ratio, surfactant concentration and osmotic effect of adding salts to the
external aqueous phase. PZQ-loaded NPs were characterized for drug content and drug release rate using HPLC, particle size,
particle size distribution and ζpotential using dynamic light scattering, and surface morphology using scanning electron
microscopy. In vitro parasitological studies were conducted to compare the schistosomicidal effect of PZQ and PZQ-PLGA
NPs.
Results
Spherical PLGA NPs with smooth surface were prepared. The physicochemical properties of the prepared NPs were
investigated and the optimum formulation was selected. The selected formulation was 200.1±4.68nm in diameter with
homogenous size distribution (PDI0.19±0.02) and negatively charged surface (-21.4±1.1mV). PZQ- loaded PLGA NPs
showed sustained release profile from the optimum formulation with the highest encapsulation efficiency and drug loading
(77.49±2.47% and 38.59±2.47% respectively) and higher schistosomicidal effect.
Conclusion
PZQ-loaded PLGA NPs could be a potential preliminary delivery system for treatment of Schistosomiasis.
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